AUTHOR INDEX

Page references to supplements 1 (August 1995) and 2 (October 1995) are preceded, respectively, by S1: and S2:

Abboud, H. A., 982
Abecassis, M., 785
Abraham, A. A., 286
Adrogué, H. J., 321
Agodoa, Y. C., S2:1
Akhtar, M., 368
Alamo, C., 668
Albers, F., 34
Al Eisa, A., 368
Allon, M., 607
Al Meshari, K., 368
Alpers, C. E., 662
Alsina, J., 947
Anandan, J. V., 469
Anasetti, C., 532
Andrés, A., 668
Andreucci, V. E., 27
Antsaklis, A., 781
Appel, G. B., 193
Arakawa, M., 13
Araque, A., 668
Audouin, J., 84
Avram, M. M., 88, 209
Aymard, B., 84
Azrolan, N., 170

Baba, M., 72
Bahnisch, J., 727
Bain, R. P., 904
Baker, F., 632
Bargman, J., S1:1
Barrios, R., 1
Barth, R. H., 80
Batuman, V., 825
Baxter, R., 377
Bell, R. A., 577
Bellou, A., 84
Benigni, A., 934
Bennett, W. M., 556
Bergman, S. M., 68
Bergström, J., 229, 963
Berman, D. H., 202
Bernardo, M. V., 321
Beto, J., 995
Bia, M. J., 387, 495
Bloembergen, W. E., S2:1
Blue, J., 918
Bódi, I., 286
Boldorini, R., 446
Bonomini, L., 209
Bootsma, H., 595
Borra, S. I., 788
Bostom, A., 170
Breedveld, F. C., 595
Brennan, D. C., 701
Brenner, B. M., 91
Brown, A., 852
Brown, C. D., 170, 202
Brunner, H. R., 108
Brunori, G., 475
Bruzzi, I., 934
Bryan, J., 353
Bucala, R., 875
Burgess, E., S1:1
Burke, B., 527
Burnier, M., 108
Burton, M. E., 381
Butterly, D. W., 34, 487

Cahill, B., 527
Cai, H., 825
Campbell, S. C., 658
Campesa, V. M., 861
Campise, M., 727
Cao, J. T. H., 1
Carrera, M., 947
Carreras, L., 947
Carroll, C. E., S2:1
Casanova, S., 446
Cerezo, S., 845
Chan, S. K., 508
Chattopadhyay, J., 209
Chawla, K., 649
Chirawong, P., 300
Chou, S.-Y., 116
Cianciaruso, B., 475
Clarkson, A. R., 727
Coburn, J. W., 831
Coffman, T. M., 487
Cohen, D. J., 193
Colburn, W. A., 918
Cole, E. H., 580
Collins, A. J., 918
Conger, J. D., 565
Conlon, P. J., 34
Conte, G., 27
Cook, W. J., 68
Cooper, J., 785
Coremans, I. E. M., 595
Coventry, S., 740
Cowley, B. D., Jr., 501
Crook, E. D., 68
Cruzado, J. M., 947
Culp, K., 341

Daha, M. R., 595
D'Amico, G., 124
Davies, S. J., 353
Davis, C. L., 662
Davison, J. M., 54
D'Cruz, I. A., 956
De Jong, P. E., 187
DeLuca, H., 852
Denda, M., 852
De Nicola, L., 27
Depestre, M., 649
De Vecchi, A., 475
De Zeeuw, D., 187
Diamond, J. R., 133
Di Belgiojoso, G. B., 446
Digenis, G. E., 781
Dillon, J. J., 432
Ding, H., 248, 818
Dolson, G. M., 321
Dumler, F., 469

Eberhardt, M. S., 308
Egrie, J. C., 331
Eknoyan, G., 797, 801
Ellis, K. J., 321
Endo, F., 732
England, B. K., 242
Enia, G., 475
Eschbach, J. W., 331
Esnault, V. L. M., 439

Fein, P., 209
Ferrario, F., 124
Fidler, V., 187
Figliuzzi, M., 934
Finch, J., 852
Findon, G., 765
Fine, A., 751
Fink, H., 292
Finlay, A., 327
Firanek, C. A., 47
Fischer, F.-P., 924
Fishbane, S., 41
Flanigan, M., 341
Flye, M. W., 701
Foulks, C. J., 995
Frazao, J., 831
Freedman, Z., 674
Frei, G. L., 41
Friedman, E. A., 170, 202
Fukatsu, A., 72
Fukuda, K., 602
Fukushima, M., 952
Furukawa, T., 889

Gall, M.-A., 898
Gallay, B. J., 662
Ganten, D., 727
Gao, X.-L., 248

AUTHOR INDEX

Page references to supplements 1 (August 1995) and 2 (October 1995) are preceded, respectively, by S1: and S2:

Abboud, H. A., 982
Abecassis, M., 785
Abraham, A. A., 286
Adrogué, H. J., 321
Agodoa, Y. C., S2:1
Akhtar, M., 368
Alamo, C., 668
Albers, F., 34
Al Eisa, A., 368
Allon, M., 607
Al Meshari, K., 368
Alpers, C. E., 662
Alsina, J., 947
Anandan, J. V., 469
Anasetti, C., 532
Andrés, A., 668
Andreucci, V. E., 27
Antsaklis, A., 781
Appel, G. B., 193
Arakawa, M., 13
Araque, A., 668
Audouin, J., 84
Avram, M. M., 88, 209
Aymard, B., 84
Azrolan, N., 170

Baba, M., 72
Bahnisch, J., 727
Bain, R. P., 904
Baker, F., 632
Bargman, J., S1:1
Barrios, R., 1
Barth, R. H., 80
Batuman, V., 825
Baxter, R., 377
Bell, R. A., 577
Bellou, A., 84
Benigni, A., 934
Bennett, W. M., 556
Bergman, S. M., 68
Bergström, J., 229, 963
Berman, D. H., 202
Bernardo, M. V., 321
Beto, J., 995
Bia, M. J., 387, 495
Bloembergen, W. E., S2:1
Blue, J., 918
Bódi, I., 286
Boldorini, R., 446
Bonomini, L., 209
Bootsma, H., 595
Borra, S. I., 788
Bostom, A., 170
Breedveld, F. C., 595
Brennan, D. C., 701
Brenner, B. M., 91
Brown, A., 852
Brown, C. D., 170, 202
Brunner, H. R., 108
Brunori, G., 475
Bruzzi, I., 934
Bryan, J., 353
Bucala, R., 875
Burgess, E., S1:1
Burke, B., 527
Burnier, M., 108
Burton, M. E., 381
Butterly, D. W., 34, 487

Cahill, B., 527
Cai, H., 825
Campbell, S. C., 658
Campesa, V. M., 861
Campise, M., 727
Cao, J. T. H., 1
Carrera, M., 947
Carreras, L., 947
Carroll, C. E., S2:1
Casanova, S., 446
Cerezo, S., 845
Chan, S. K., 508
Chattopadhyay, J., 209
Chawla, K., 649
Chirawong, P., 300
Chou, S.-Y., 116
Cianciaruso, B., 475
Clarkson, A. R., 727
Coburn, J. W., 831
Coffman, T. M., 487
Cohen, D. J., 193
Colburn, W. A., 918
Cole, E. H., 580
Collins, A. J., 918
Conger, J. D., 565
Conlon, P. J., 34
Conte, G., 27
Cook, W. J., 68
Cooper, J., 785
Coremans, I. E. M., 595
Coventry, S., 740
Cowley, B. D., Jr., 501
Crook, E. D., 68
Cruzado, J. M., 947
Culp, K., 341

Daha, M. R., 595
D'Amico, G., 124
Davies, S. J., 353
Davis, C. L., 662
Davison, J. M., 54
D'Cruz, I. A., 956
De Jong, P. E., 187
DeLuca, H., 852
Denda, M., 852
De Nicola, L., 27
Depestre, M., 649
De Vecchi, A., 475
De Zeeuw, D., 187
Diamond, J. R., 133
Di Belgiojoso, G. B., 446
Digenis, G. E., 781
Dillon, J. J., 432
Ding, H., 248, 818
Dolson, G. M., 321
Dumler, F., 469

Eberhardt, M. S., 308
Egrie, J. C., 331
Eknoyan, G., 797, 801
Ellis, K. J., 321
Endo, F., 732
England, B. K., 242
Enia, G., 475
Eschbach, J. W., 331
Esnault, V. L. M., 439

Fein, P., 209
Ferrario, F., 124
Fidler, V., 187
Figliuzzi, M., 934
Finch, J., 852
Findon, G., 765
Fine, A., 751
Fink, H., 292
Finlay, A., 327
Firanek, C. A., 47
Fischer, F.-P., 924
Fishbane, S., 41
Flanigan, M., 341
Flye, M. W., 701
Foulks, C. J., 995
Frazao, J., 831
Freedman, Z., 674
Frei, G. L., 41
Friedman, E. A., 170, 202
Fukatsu, A., 72
Fukuda, K., 602
Fukushima, M., 952
Furukawa, T., 889

Gall, M.-A., 898
Gallay, B. J., 662
Ganten, D., 727
Gao, X.-L., 248

Gardner, K. D., Jr., 691
Gattone, V. H., II, 501
Genderini, A., 446
Geng, Z., 622
Gile, R. D., 501
Gimenez, L. F., 331
Girndt, M., 454
Goldblum, R., 590
Golstein, J., 995
Gomez, R. A., 409
Goodkin, D. A., 331
Gordon, B. R., 162
Goya, T., 602
Graber, S. E., 331
Grantham, J. J., 501
Greenfield, R. A., 381
Greenwell, G., 590
Greer, J. W., S2:1
Grégoire, M.-J., 84
Griffin, A. D., 658
Grinyó, J. M., 947
Guan, S., 825
Guest, S. S., 377
Guijarro, C., 152
Gunnells, J. C., 34, 487

Haas, M., 740
Hakim, R. M., 256
Halstenson, C. E., 918
Hamai, K., 511
Hanai, J., 774
Haramoto, T., 62
Harder, J., 590
Harland, R. C., 520
Harmon, K. R., 527
Harrell, F. E., Jr., 487
Hartung, R., 727
Hatton, R. C., 327
Hattori, S., 732
Hawkins, P. N., 267
Hawley, C. M., 658
Hawthorne, V. M., 308
Hay, E. D., 678
Hayashi, K., 889
Hebert, L. A., 432
Held, P. J., S2:1
Hemmelder, M. H., 187
Hercz, G., 836
Herman, W. H., 308
Hervas, J., 845
Hestin, D., 84
Higashi, F., 889
Hill, D. J., S2:1
Hironaka, K., 62
Hirsch, D. J., 385
Hirschberg, R., 818
Höffken, B., 292
Hogg, R. J., 792
Holzman, E., S2:1
Hommel, E., 99
Hong, S. K., 722
Howell, D. N., 34, 520
Hoye, E., 178
Huang, W. H., 220
Hübel, E., 924
Hubert, J., 84
Huycke, M. M., 381
Hwang, H. R., 722

Ichida, S., 72
Ichihara, A., 889
Ikeda, H., 952
Ikizler, T. A., 256
Imai, H., 511
Ing, T. S., 508
Ishidoya, S., 141
Ishimura, E., 654
Islam, A., 814
Ito, Y., 72
Itoh, K., 952

Jackson, K., 716
Jadoul, M., 549
Jindal, K. K., 385, S1:1
Johanson, W. G., 554
Johnson, D. W., 658
Johnson, R. J., 57, 662
Joles, J. A., 178
Jones, C. A., S2:1
Jones, H., Jr., 178
Jones, M. R., 963

Kalantar-Zadeh, K., 292
Kallenberg, C. G. M., 595
Kaplan, B., 785
Karashima, S., 732
Kashgarian, M., 654
Kasiske, B. L., 152, 387
Kater, L., 595
Katsumata, H., 889
Kawasaki, K., 13
Kaysen, G. A., 178
Keane, W. F., 152
Keshaviah, P. R., 963
Kessler, M., 84
Ketz, L.-A. D., S2:1
Kiefer, T., 924
Kim, C.-W., 654
Kim, G. S., 722
Kim, S. B., 722
Kim, Y., 152
Kimmel, P. L., 286
Kirsch, C. M., 377
Kitaoka, M., 774
Klahr, S., 88, 141, 797
Kleiner, M., 292
Kleinfeld, M., 788
Kliger, A., 495
Kogosov, E., 861
Köhler, H., 454
Komatsuda, A., 511
Konen, J. C., 577
Kontessis, P. S., 781
Kopple, J. D., 248, 475, 818, 963, 995
Korbet, S. M., 47, 516
Koss, M., 861
Krishnan, B., 1
Kryger, M. H., 751
Kuhlmann, U., 924
Kulvicki, A., 590
Kumagai, K., 889
Kuo, P., 643
Kuroda, T., 13
Kurtzman, N. A., 866
Kusumoto, T., 952

Labonia, W. D., 757
Lager, D., 785
Langdon, L. O., 556
Laohapand, T., 300
Laufer, J., 960
Lauria, R., 27
Lazarus, J. M., 331
Leblanc, M., 910
Lederlin, P., 84
Lee, H. S., 152
Lee, K.-U., 722
Levin, A., S1:1
Levine, D. M., 162
Levine, G. N., S2:1
Levy, E., 495
Lew, N. L., 220
Lewis, E. J., 432, 904
Li, C. S., 508
Libetta, C., 27
Linas, S. L., 586
Lindsay, R. M., 963
Liu, K., 520
Llach, F., 845
Lockwood, C. M., 439
Lorber, M., 495
Lotan, D., 960
Lowrie, E. G., 220
Luft, F. C., 292

McCauley, J., 671
Mackenzie, H. S., 91
McPhedran, P., 495
Madu, E. C., 956
Maesaka, J., 41
Maiorca, R., 475
Makino, H., 62
Malasit, P., 300
Malluche, H. H., 622
Maloney, N. A., 836
Manivel, J. C., 527
Mañá, J., 947
Marumo, K., 889
Matsuda, I., 732
Matsuo, S., 72
Matsuura, T., 732
Mauger, E. A., S2:1
Mayer, G., 727
Mazzucco, G., 446

Melero, M., 668
Memoli, B., 27
Menachery, S. J., 716
Mendelssohn, D. C., 580
Mettang, T., 924
Middendorf, D. F., 432
Miles, A. M. V., 80
Miller, C. C., III, 347
Miller, R. B., 527
Miller, T., 765
Minda, S. A., 487
Mitch, W. E., 242
Mittman, N., 209
Miura, A. B., 511
Miyakawa, H., 774
Mizuno, M., 72
Mohanakumar, T., 701
Monga, G., 446
Monier-Faugere, M.-C., 622
Moon, D. H., 722
Moorhouse, J., 632
Morabito, A., 27
Moran, J., 963
Moreno, L., 910
Morich, D., 532
Morigi, M., 934
Morii, H., 654
Morita, T., 13
Morrissey, J., 141, 852
Motta, M., 446
Muirhead, N., S1:1
Murphy, K. D., 634

Naguib, M. T., 381
Nakamoto, H., 889
Nakamoto, M., 602
Nakato, T., 952
Nakazato, H., 732
Neal, D. E., Jr., 590
Neugarten, J., 147, 362
Nielsen, F. S., 898
Nilwarangkur, S., 300
Nimmannit, S., 300
Nishitani, H., 654
Nishizawa, Y., 654
Nolan, C. R., 634
Nolin, L., S1:1
Nolph, K. D., 963
Noris, M., 541
Norwood, V. F., 409
Nussberger, J., 108

O'Donnell, M. P., 152, 501
Ogborn, M. R., 942
Ohishi, A., 889
Ohtani, H., 511
Ojo, A. O., S2:1
Okamoto, D. M., 331
Okumura, M., 654
Oldroyd, S., 934
Ong-aj-yooth, L., 300
Ota, Z., 62

Pacchiano, G., 27
Paganini, E. P., 331, 910
Paller, M. S., 527
Palmieri, G., 27
Panarello, G., 475
Papageorgiou, I., 781
Paraskevopoulos, A., 781
Parfrey, P., S1:1
Parichatikanond, P., 300
Park, J. S., 722
Park, J. Y., 722
Parving, H.-H., 99, 898
Patel, R. V., 469
Pattison, J. M., 643
Pechère-Bertschi, A., 108
Pederson, J. A., 381
Pei, Y., 836
Pennington, L. R., 381
Pepys, M. B., 267
Perazella, M., 495
Perinbasekar, S., 649
Peter, J. B., 432
Petersen, J., 590, 643
Petrie, J. J. B., 658
Phillips, L., 353
Phol, M. A., 904
Pietsch, M., 454
Pinette, G., 942
Piraino, B., 995
Pollak, V. E., 535
Ponticelli, C., 727
Port, F. K., S2:1
Portales, I. T., 327
Porush, J. G., 116
Poveda, R., 947
Praga, M., 668
Prakash, R., 321, 347
Prasad, G. V. R., 373
Price, S. R., 242
Przybelski, R. J., 918
Purighalla, R., 671
Puschett, D. B., 825
Puschett, J. B., 825

Qi, Q., 622
Querques, M., 475

Radhakrishnan, J., 193
Rambausek, M., 808
Randhawa, P., 671
Rappini, P., 781
Rastaldi, M. P., 124
Reaich, D., 242
Remuzzi, G., 541, 934
Renoult, E., 84
Rie, J., 362
Rigby, R. J., 658
Ritter, C., 852
Ritz, E., 727, 808
Robbins, R. C., 643
Roberts, K. G., 170
Robinson, O. P., 910

Rodby, R., 34
Rodby, R. A., 904
Rodriguez, M., 668
Rohde, R. D., 904
Romano, P., 27
Ronco, P., 934
Rosansky, S. J., 716
Ross, E. A., 327
Rossi, N. F., 373
Rossing, P., 99
Rothstein, M., 341
Royal, H. D., 614
Russell, G. I., 353
Russell, L., 353
Rydel, J. J., 516
Ryuzaki, M., 889

Sabatini, S., 866
Sado, Y., 72
Saeki, T., 13
Saenz, K. P., 634
Sakuraba, H., 952
Salem, M. M., 461
Samsa, G. P., 487
Sanfilippo, F. P., 520
Santoro, S., 614
Sareen, S., 942
Saruta, T., 889
Sasaki, T., 62
Schenk, U., 924
Schiff, M. J., 22
Schmidt, S., 727
Schultz, M. F., 662
Schwartz, M. M., 516
Scialó, A., 27
Segre, G. V., 836
Sehgal, V., 193
Shanklin, N., 607
Shapiro, R., 671
Sharon, Z., 904
Shayakul, C., 300
Sherrard, D. J., 836
Shih, D. J., 516
Shikata, K., 62
Shoji, S., 654
Short, A. K., 439
Silbiger, S. R., 147, 362
Sinaiko, A. R., 527
Singh, H., 586
Slatopolsky, E., 852
Sloand, J. A., 22
Smidt, U. M., 99
Smith, D. A., S2:1
Smith, S. R., 487
Smorgorzewski, M., 814
Sorooshian, M., 377
Spargo, B. H., 740
Spital, A., 674
Spohn, M., 866
Spronk, P. E., 595
Stannard, D. C., S2:1

Stefanski, A., 808
Stein, A., 632
Stein, G., 727
Stier, E., 727
Stragier, A., 549
Strawderman, R. L., S2:1
Striker, G. E., 399, 998
Strippoli, P., 475
Sturgiss, S. N., 54
Suki, W. N., 1, 347
Summerson, J. H., 577
Suzuki, H., 889
Suzuki, K., 13
Swan, S. K., 501, 918

Takahashi, K., 62
Tan, S. Y., 267
Tanemoto, M., 774
Tapolyai, M., 910
Taylor, L., 341
Tedeschi, P. J., S2:1
Teehan, B. P., 963
Theodore, J., 643
Thomas, C. A., III, 634
Thomas, L., 170
Thomas, S., 924
Tomlinson-Marshall, L. A., 308
Touchette, M. A., 469
Traverso, G., 475
Trillo, A. A., 385
Truong, L. D., 1
Tsuchiyama, Y., 952
Turenne, M. N., S2:1

Uchida, S., 774
Uemura, T., 732
Ushijima, T., 732

Valantine, V., 643
Valeri, A., 193
Van der Voort, E. A. M., 595
Vanichakarn, S., 300
Van Stone, J. C., 331
Van Tol, A., 178
Vareesangthip, K., 300
Vasuvattakul, S., 300
Viglino, G., 475
Vonesh, E. F., 47, 475

Waeber, B., 108
Wagener, D. K., 308
Wagner, C. M., 716
Wakui, H., 511
Walker, J. V., 532
Walker, S., 751
Wall, D. R., 658
Walls, J., 632
Wang, M., 836
Watanabe, Y., 654
Webb, R. L., S2:1
Wendericks, D., 549
Wenzel, U. O., 982
Wigfall, D. R., 520
Windus, D. W., 614
Wingard, R. L., 256
Wolfe, R. A., S2:1
Wong, F. K. M., 508
Wood, C. L., S2:1
Woodroffe, A. J., 727
Wünsch, H., 292

Yago, M., 774
Yasuda, T., 511
Yasunaga, C., 602
Yatzidis, H., 924
Yokoi, T., 952
Yoshida, S., 952
Young, E. W., S2:1
Young, J., 377

Zarowitz, B. J., 469
Zerefos, N., 781
Zhao, Z. H., 170
Zoja, C., 934
Zuk, A., 678

SUBJECT INDEX

Page references to supplements 1 (August 1995) and 2 (October 1995) are preceded, respectively, by S1: and S2:

A elegans (Apophysomyces elegans) infection in renal transplant recipients, 381-384
A niger (Aspergillus niger) peritonitis on CAPD, therapy of, survival with, and return to CAPD, 80-83
Abdominal pain, acute, hepatic infarction and, in SLE patients on HD, 785-787
ABIM (American Board of Internal Medicine) Recertification program, 554-555
Abnormal growth processes, angiotensins in, 425-426
ABO blood type in renal transplantation for ESRD, USRDS 1995 ADR on, S2:102-103
ACAs, *see* Anticardiolipin antibodies
Acceptance into ESRD therapy, S2:177-179
Access
  to USRDS data, S2:173
  see also Access to renal transplantation for ESRD, USRDS 1995 ADR on *and entries beginning with terms*: Vascular access
Access to renal transplantation for ESRD, USRDS 1995 ADR on
  adult, S2:105-110
  pediatric, S2:119-123
ACE, *see* Angiotensin-converting enzyme; Angiotensin I-converting enzyme gene; Angiotensin-converting enzyme inhibitor(s)
Acid-base status, *see* pH
Acidosis, *see* Metabolic acidosis
ACKD (acquired cystic kidney disease), *see* Renal cell carcinoma in ACKD
Acknowledgment for use of USRDS data, S2:25
Acquired cystic kidney disease, *see* Renal cell carcinoma in ACKD
Acquired oligonephropathy, diabetic nephropathy and, 898-903
Acronyms used in USRDS 1995 ADR, S2:9-11
Actual body weight (BW), defined, urea kinetics and, 964
Acute abdominal pain, hepatic infarction and, in SLE patients on HD, 785-787
Acute interstitial nephritis (AIN), triazolam-induced, eosinophilic infiltration in NS with, 62-67

Acute myocardial infarction, streptokinase for, ARF following, 508-510
Acute renal failure (ARF), 565-576
ciprofloxacin-associated, 516-519
definitions of, 556
following streptokinase for acute myocardial infarction, 508-510
low-dose dopamine infusions reversing rIL-2-induced, in cancer patients, 27-33
treatment of, *see* Therapy of ARF
Acute serum K (potassium) decrease, hypertension due to, in ESRD patients on HD, 321-326
Acute water loading, tubular effects of, 108-115
Adenosine monophosphate, cyclic, as mediator in Pi transport inhibition by KW-3902, 825-830
Adhesion molecules in GN, 544-546
Adjustment (standardization) of rates in USRDS 1995 ADR, S2:13, S2:179-180
Administration of rHuEPO
IV versus subcutaneous, for HD patients with ESRD, 331-340
recommendations for, S1:5-8
ADPKD (autosomal dominant polycystic kidney disease), lovastatin effects in, 501-507
ADR (Annual Data Report) of USRDS, *see* United States Renal Data System, 1995 ADR of
Adult(s)
idiopathic NS in, and incidence of FSGS, 740-750
uninephrectomy in, follow-up on, 889-897
see also specific conditions
Adult cadaveric kidney, pediatric transplantation for CRF with, metastatic renal cell carcinoma in, 960-962
Advanced glycosylation end (AGE) products in diabetic nephropathy and diabetic vascular disease, 875-888
aminoguanidine inhibiting, 884
biochemistry of, 876-877
effects of, on blood flow and vascular reactivity, 879-880
effects of, on long-lived ECM proteins, 877-878
lipid- and lipoprotein-advanced glycosylation, 881-884
renal effects of, 879
tissue responses to, 878-879
Adverse effects, rHuEPO, S1:9-12
Afferent denervation, renal, prevention of progression of renal disease with, in renal ablation model of CRF, 861-865
Affinity-purified antibodies study of ANCAs and anti-GBM in RPGN, 443
Age
of acquired oligonephropathy patients, 899
of CAPD and/or HD patients, *see* Age of CAPD and/or HD patients
of cardiac transplant patients, 195
of compulsive water drinking patients, 587
of CRF patients, hepatitis B vaccination associated with tetanus immunization in, 456
of dialysis patients with aluminum intoxication, 837
of ESRD patients, *see* Age of ESRD patients, USRDS 1995 ADR on; Age of ESRD patients on CAPD and/or HD
of familial FSGS patients, 37
of heart-lung transplant recipients, 644
of HIV-associated nephropathy patients, 448
of hypertensive patients, *see* Age of hypertensive patients
of IgAN patients, 728
of NIDDM patients, GFR and, 724
of NS patients, 172
of PD patients, survival and, 221, 223, 224
of peritonitis patients, 48, 633
of pregnant patients with primary glomerular disease, 189
of pyelonephritis patients, 597
of renal transplant patients, *see* Age of renal transplant patients
of RPGN patients, 14
of uremic patients, *see* Age of uremic patients
U.S. trends in renal disease mortality and morbidity by (1979-1990), 310-316
see also Adult(s); Young patients *and entries beginning with term*: Pediatric
Age of CAPD and/or HD patients
malnutrition and, 354-356, 378, 478-480
receiving DCLHb, 919
see also Age of CAPD and/or HD patients, survival and; Age of ESRD patients on CAPD and/or HD
Age of CAPD and/or HD patients, survival and
malnutrition and, 354-356
markers for, 213, 214, 216
predictors of, 221, 223, 224
serum PTH levels, bone turnover and, 626
see also Age of ESRD patients on CAPD and/or HD
Age of ESRD patients, USRDS 1995 ADR on
causes of death and, S2:89, S2:90
Medicare and non-Medicare patients, S2:33, S2:35
mortality rate and, S2:72-73
pediatric patients, S2:116
remaining years of life and, S2:82
RRT modality and, S2:56, S2:57
treatment incidence and, S2:40-41
vascular access and, S2:143-144, S2:146
Age of ESRD patients on CAPD and/or HD
critically ill, vancomycin removal in, 470
hypertension and, *see* Age of ESRD patients on CAPD and/or HD, hypertension and
PTFE graft thrombosis and, 342, 348
on rHuEPO therapy, 42, 332
Age of ESRD patients on CAPD and/or HD, hypertension and
due to acute serum K decrease, 323
effects of antihypertensive agents and, 462, 463
Age of hypertensive patients
and circadian variations in BP, 717, 719
with diabetic nephropathy, 100, 104
with microalbuminuria, 578
see also Age of ESRD patients on CAPD and/or HD, hypertension and
AGE (advanced glycosylation end) products, *see* Advanced glycosylation end products in diabetic nephropathy and diabetic vascular disease
Age of renal transplant patients
CsA withdrawal and, 489, 491
erythrocytosis and, 496
Age of uremic patients, 24
and sleep complaints, 752, 753, 755-756

AIN (acute interstitial nephritis), triazolam-induced, eosinophilic infiltration in NS with, 62-67
Al, *see* Aluminum toxicity
Albumin
in CAPD patients, survival and, 355, 356
effects of, on synthesis and secretion of proximal tubular cell ET-1, 934-941
and hereditary analbuminemia in NS, 178-186
and malnutrition on CAPD and HD, 479, 480
in MPO-ANCA-positive crescentic GN with Graves' disease, 755
serum, *see* Serum albumin
in severe hypercalcemia with renal failure, 675
and survival on PD and/or HD, 221, 223, 224
urinary excretion of, *see* Albuminuria; Urinary excretion, albumin
Albuminuria
in acquired oligonephropathy patients, 900
in hypertensive diabetic nephropathy, 101
see also Microalbuminuria; Proteinuria
Albuterol, effects of, on dialytic K removal in hyperkalemia of ESRD, 607-613
Aldosterone, circadian BP variations and, 718, 719
Alkaline phosphatase
IV calcitriol effects on, 847
levels of, and survival in PD, 221
serum, and bone turnover in ESRD patients on CAPD, 627
Allele frequencies of I/D polymorphism of angiotensin 1-converting enzyme gene, 729
Allowed charges for vascular access in ESRD, USRDS 1995 ADR on, S2:145
defined, S2:142-143
Alpha$_2$ (α_2)-antiplasmin, Ancrod effects on, in SLE and DPLN, 538
Alport's syndrome, splicing mutations of COL4A5 gene in, 732-739
Alternate-day prednisone supplementation, fish oil and, in young IgA nephropathy patients, 792-796
Aluminum (Al) toxicity
relationship between intact PTH and bone histomorphometry in dialysis patients without, 836-844
and resistance to rHuEPO, S1:13-14
Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis
American Board of Internal Medicine (ABIM) Recertification program, 554-555
Amino acids
branched-chain, metabolism of, in metabolic acidosis, 243
loss of, on HD and CAPD, 237
Aminoguidine, advanced glycosylation inhibited by, 884
Amphotericin B liquid complex for *A elegans* infection in renal transplant recipients, 381-384
Amyloid P scintigraphy, *see* Radiolabeled serum amyloid P scintigraphy of amyloidosis
Amyloidosis, 267-285
diagnosis and monitoring of, 268-270; *see also* Radiolabeled serum amyloid P scintigraphy of amyloidosis
treatment of, *see* Amyloidosis, treatment of
Amyloidosis, treatment of, 270-285
with CAPD, 279-281
of HD-related β_2M amyloidosis, 277-279
of hereditary amyloidosis and familial amyloid polyneuropathy, 279-280
of monoclonal immunoglobulin amyloidosis, 274-277
of reactive systemic amyloidosis, 271-274
with renal transplantation, *see* Renal transplantation for amyloidosis
Analbuminemia, hereditary, in NS, 178-186
Analytical methods used in USRDS 1995 ADR, S2:174-186
for cost effectiveness, S2:185-186
Death Notification Form and, S2:174, S2:177
differences between 1994 and 1995 ADR, S2:174-175
for expected remaining years, S2:183
"fifteen month rule" and, S2:176-177
geography in, S2:177
for hospitalization, S2:184-185
for incidence and prevalence, S2:174, S2:177-179
for mortality, S2:85-86, S2:174, S2:180-182
and new data in database, S2:174-177
for patient survival, S2:182-183
for renal allograft survival, S2:183-184
for rHuEPO therapy, S2:184
standardization of rates and, S2:179-180
Anaphylaxis, and IgA deficiency, 520-526
ANCA, *see* Antineutrophil cytoplasmic antibody(ies)
Ancrod, effects of, on SLE and DPLN, 538
Anemia of ESRD or CRF
clinical impact of, S1:2
see also Recombinant human erythropoietin for ESRD (and or CRF)
Anergy, as mechanism of immunomodulation in DST, 708-709
Angiography of renal cell carcinoma, 4
Angiotensin(s), development and
in abnormal growth processes, 425-426
biochemistry and physiology of, 413-414
as growth modulators, 424-425
see also Renin-angiotensin system *and entries beginning with term*: Angiotensin
Angiotensin II (ANGII), role of, in obstructive nephropathy, 141-145
Angiotensin II (ANGII) receptor antagonists, tubular effects of, 108-115
Angiotensin-converting enzyme (ACE)
biochemistry and physiology of, 412-413
expression of genes of, during development, 420
Angiotensin I-converting enzyme (ACE) gene in IgAN, insertion/deletion polymorphism in, 727-731
Angiotensin-converting enzyme (ACE) inhibitor(s)
cilazapril as, progression of hypertension and uremia in PKD delayed with, 942-946
enalapril as, for erythrocytosis following renal transplantation, 495-500
in hypertensive diabetic nephropathy, 99-107
Angiotensin-generating cascades in, 409-411
Angiotensin receptors
biochemistry and physiology of, 414-416
expression of genes of, during development, 420-421
Angiotensinogen
biochemistry and physiology of, 411
expression of genes of, during development, 416-417
Anion gap

in ARF patients on HCO_3-based CRRT, 913
and survival on PD and HD, 221, 223, 224
Annual Data Report of USRDS, *see* United States Renal Data System, 1995 ADR of
Anorexia, uremic, and malnutrition on HD and/or CAPD, 231-233
Anthropometric parameters
urea kinetics and, 964-967
see also specific anthropometric parameters
Antibodies
anti-idiotypic, DST and, 709
to C1q and double-stranded DNA, changes in, and renal relapses in systemic lupus erythematosus, 595-601
monoclonal anti-CDH, renal CTH accumulation in Fabry's disease detected with, 952-955
see also Anticardiolipin antibodies; Antiglomerular basement membrane antibodies; Antineutrophil cytoplasmic antibody(ies); Antiphospholipid antibodies
Anticardiolipin antibodies (ACAs)
in maintenance HD patients, recurrent AVF thrombosis associated with, 347-352
in Sneddon's syndrome, 515
Anticholinergic drugs, compulsive water drinking due to, CRF and, 586-589
Anticoagulant, *see* Lupus anticoagulant
Anti-GBM antibodies, *see* Anti-glomerular basement membrane antibodies
Antigen(s)
hepatitis B surface, in HIV-associated nephropathy, 448
see also HLA
Antiglomerular basement membrane (anti-GBM) antibodies
ANCAs and, in RPGN, 439-445
GN with multinucleated giant cells induced by, IL-6 in, 72-79
Antihypertensive therapy
of hypertensive ESRD on HD, 461-468
see also specific antihypertensive agents; for example: Angiotensin-converting enzyme inhibitor(s)
Anti-idiotypic antibodies, DST and, 709
Anti-inflammatory therapy
of β_2M amyloidosis, 278
of reactive amyloidosis, 271-272
Antineutrophil cytoplasmic antibody(ies) (ANCA), 57-61
see also Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis; Antineutrophil cytoplasmic antibody(ies) in RPGN
Antineutrophil cytoplasmic antibody (ANCA)-positive crescentic glomerulonephritis (GN)
with Graves's disease, complications in, 774-780
thrombotic microangiopathy and, 385-386
Antineutrophil cytoplasmic antibody(ies) (ANCA) in RPGN, 13-21
with anti-GBM antibodies, 439-445
Antioxidant effects of sex hormones on lipids, 148-149
Antiphospholipid antibodies (APAs)
ACAs and, with recurrent AVF thrombosis in maintenance HD patients, 347-352
in Sneddon's syndrome, 515
and vascular thrombosis in SLE patients on HD, 785-787
Antiphospholipid syndrome (APS), and renal infarction in mixed CTD, 649-653
α_2 (alpha$_2$)-Antiplasmin, Ancrod effects on, in SLE and DPLN, 538
APAs, *see* Antiphospholipid antibodies
APD, *see* Automated peritoneal dialysis
Apolipoprotein A (apo A) phenotype in NS, 170-177
Apolipoprotein A-I (apo A-I), effects of oncotic pressure on metabolism of, in NS, 178-186
Apophysomyces elegans (A elegans) infection in renal transplant recipients, 381-384
Apoptosis in HIV-associated nephropathy, 286-291
Appetite, comorbidity, Kt/V and, in CAPD patients, survival and, 353-361
APS (antiphospholipid syndrome), and renal infarction in mixed CTD, 649-653
ARF, *see* Acute renal failure
Arsenic intoxication associated with tubulointerstitial nephritis, 373-376
Arterial repositioning, superficial, for chronic HD, indications for, and prognosis of, 602-606
Arterio-occlusive disorder, Sneddon's syndrome as, *see* Sneddon's syndrome, as arterio-occlusive disorder
Arteriovenous fistulas (AVFs)
native, HD effects on platelet deposition in, 614-621
see also Arteriovenous fistulas, thrombosis of, on HD
Arteriovenous fistulas (AVFs), thrombosis of, on HD, 341-352
in ESRD patients, 341-346
recurrent thrombosis, ACA in maintenance HD patients associated with, 347-352
Ascites, idiopathic dialysis, renal transplantation for, 668-670
Aspergillus niger (A niger) peritonitis on CAPD, survival with, therapy of, and return to CAPD, 80-83
Assessment, *see* Evaluation
Atherosclerosis
Lp(a) levels as risk factor for, 166-167
see also Advanced glycosylation end products in diabetic nephropathy and diabetic vascular disease
Atrophy, tubular, tubular damage and interstitial mononuclear leukocytes in GN, 129
Autoimmunity in RPGN, 439-445
Automated core biopsy device in percutaneous renal biopsy, outcome and, 580-585
Automated peritoneal dialysis (APD)
death risk predictors with, 220-228
S aureus and *S epidermidis* peritonitis on, 47-53
Autosomal dominant polycystic kidney disease (ADPKD), lovastatin effects in, 501-507
AVFs, *see* Arteriovenous fistulas

Bacterial clearance in CAPD peritonitis, 765-773
BCAAs (branched-chain amino acids), metabolism of, in metabolic acidosis, 243
Berger's disease, *see* IgA nephropathy
Beta$_2$-microglobulin (β_2M) amyloidosis, treatment of, 277-279
Bicarbonate, *see* HCO_3
Bilirubin
enalapril effects on, 497
levels of, and survival on PD and HD, 221, 223, 224
Billing records for vascular access, as source of cost data, S2:150-151

Biochemical data
on lupus nephritis, 302
see also specific biochemical data
Biochemical Scientific Advisory Committee (B-SAC), USRDS, S2:6
Biochemistry
of AGE products, 876-877
of RAS components, 411-416
see also Biochemical data
Biocompatible membranes
in dialysis for ARF, 571
and protein catabolism, malnutrition on HD and/or CAPD and, 237-238
Biopsy, *see* Bone biopsy; Renal biopsy
Birth, nephron number at, essential hypertension and, 91-98
Birth weight, nephron formation and, 94
BK (polyoma) virus infection in renal allografts, renal biopsy of, 671-673
Bladder, pH effects on Ca transport in, 866-872
Bleeding
effects of low-dose transdermal estrogens on, in uremia, 22-26
and resistance to rHuEPO, S1:14
Bleeding time (BT), effects of low-dose transdermal estrogens on, in uremia, 22-26
Blood flow, AGE products effects on, 879-880
Blood pressure (BP)
albuterol effects on, 610
Ancrod effects on, in SLE and DPLN, 538
circadian variations in, renal function versus, 716-721
in heart-lung transplant recipients, 644
kidney and, 91-92
nephron supply and, 92
of NIDDM patients, GFR and, 724
rHuEPO effects on, 203
and vascular access thrombosis in ESRD patients on HD, 343-344
see also Hypertension
Blood type, ABO, in renal transplantation for ESRD, USRDS 1995 ADR on, S2:102-103
Blood urea nitrogen, *see* BUN
Blood vessels
cerebral, livedo racemosa, nephropathy, and occlusion of, in Sneddon's syndrome, 511-515
see also entries beginning with terms: Vascular, Venous *and element*: Arter-
Body mass index
and circadian variations in BP, 717
of hypertensive patients with microalbuminuria, 578
of NIDDM patients, GFR and, 724
urea kinetics and, 966-967
of uremic HD patients with sleep complaints, 752
see also Body mass index of ESRD patients
Body mass index of ESRD patients, S2:35
vascular access type and, S2:144
Body surface urea, defined, urea kinetics and, 966
Body water, total, urea kinetics and, 966
Body weight (BW)
at birth, nephron formation and, 94
of CAPD and/or HD patients, *see* Body weight of CAPD and/or HD patients
dietary cholesterol effects on, 153
of ESRD patients, *see* Body weight of ESRD patients
urea kinetics and, 964-966, 978
of uremic HD patients with sleep complaints, 752
Body weight (BW) of CAPD and/or HD patients
malnutrition and, 478-480
and survival, 342
Body weight (BW) of ESRD patients, S2:35
critically ill, on HD, vancomycin removal in, 470
predialysis, hypertension and, 462, 463
vascular access type and, S2:144
Bone(s), *see entries beginning with term*: Bone *and element*: Oste-
Bone biopsy, 831-844
and relationship between intact PTH and bone histomorphometry in dialysis patients without aluminum toxicity, 836-844
for symptomatic hypercalcemia in diabetic ESRD patient on CAPD, 831-835
Bone marrow infusion, *see* Donor bone marrow infusion
Bone marrow transplantation, minimal change NS after CsA withdrawal in recipients of, renal biopsy of, 532-534
Bone turnover in CAPD patients, serum PTH levels and, 622-631
BP, *see* Blood pressure
Brachial artery repositioning, superficial, for chronic HD, indications for, and prognosis with, 602-606
Brain synaptosomes, PTH stimulating generation of inositol 1,4,5-triphosphate in, 814-817
Branched-chain amino acids (BCAAs), metabolism of, in metabolic acidosis, 243
Breathing events, disordered, during sleep of uremic HD patients, 753, 755
B-SAC (Biochemical Scientific Advisory Committee), USRDS, S2:6
BT (bleeding time), effects of low-dose transdermal estrogens on, in uremia, 22-26
BUN (blood urea nitrogen)
in ARF patients on HCO_3-based CRRT, 913
in Graves' disease, 775
levels of, and survival on PD and HD, 221, 224
plasma, effects of albuterol on, 610
and rhGH therapy of malnutrition on HD and/or CAPD, 263
in severe hypercalcemia and renal failure, 675
BW, *see* Body weight

C, *see* Complement; Complement 1q
Ca (calcium)
in ARF patients on HCO_3-based CRRT, 913
and Ca connection in history of parathyroid glands, 804-805
L-carnitine and rHuEPO effects on, 761
and effects of IGF-1 on renal handling of P, Na and, in normal population, 818-824
levels of, and survival on PD and HD, 221
pH effects on transport of, in bladder, 866-872
serum, *see* Serum Ca
see also Hypercalcemia; Parathyroid hormone, Ca, P *and entries beginning with acronym*: Ca
Ca (calcium) channel blockers in ARF therapy, 568-570

Ca (calcium) dialysate, traditional versus low, and peritonitis rate, 632-633
Ca^{45} ($calcium^{45}$) fluxes, unidirectional, in bladder, pH effects on, 866-872
Cadaveric renal graft
  adult, metastatic renal cell carcinoma in pediatric recipient of, 960-962
  see also Cadaveric graft survival in ESRD, USRDS 1995 ADR on
Cadaveric renal graft survival in ESRD, USRDS 1995 ADR on, S2:97-101
  analytic methods to determine, S2:183
  trends in, S2:99-101
Cadherins in epithelial-mesenchymal transformation, 678-689
Calcific mitral stenosis, progression to, in ESRD, 956-959
Calcitriol [$1,25(OH)_2D_2$]
  in hypercalcemia, *see* Calcitriol in hypercalcemia
  IV, dosing of, in dialysis patients with severe HPHT, 845-851
Calcitriol [$1,25(OH)_2D_2$] in hypercalcemia
  analog of, suppressing PTH secretion in uremia in absence of hypercalcemia, 852-860
  in severe hypercalcemia with renal failure, 675
Calcium, *see* Ca; Ca channel blockers; Ca dialysate; Ca^{45} fluxes
Calorie malnutrition, *see* Malnutrition on HD and/or CAPD
cAMP (cyclic adenosine monophosphate), as mediator in Pi transport inhibition by KW-3902, 825-830
Cancer, *see* Malignancy
CAPD, *see* Continuous ambulatory peritoneal dialysis
Carbohydrate metabolism, PTH effects on, 810
Carbon dioxide (CO_2) in ARF patients on HCO_3-based CRRT, 913
Cardiac transplantation, *see* Heart transplantation
Cardiomyopathy, and role of parathyroid glands in uremia, 808-813
Cardiopulmonary recirculation, and dialysis dose, 973-974
L-Carnitine, effects of, on anemia of patients treated with rHuEPO, 757-764
Carpotarsal osteolysis with nephropathy, long-term HD for, 788-791
Case Mix Adequacy (CMA) Study, USRDS, S2:172
Case Mix Severity Study, USRDS, S2:170
Casts, urinary red and white blood cell, relationship between onset of renal relapse of SLE and, 432-438
Catabolic rate, *see* Protein catabolic rate
Catabolism, *see* Protein catabolism
Caveats on release of USRDS data, S2:29
C-C chemokines, renal disease and, 984, 986-987
CC (Coordinating Center) of The University of Michigan, S2:5-6
CCPD (continuous cycling peritoneal dialysis), USRDS 1995 ADR on, *see* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1995 ADR on
Cell proliferation
  in ADPKD, 501-507
  effects of sex hormones on, 148-149
Cellular hypoxia in diabetes, 202-208
Census population base of USRDS 1995 ADR, S2:178
Central nervous system, PTH and
  PTH action on central nervous system, 810-811
  PTH stimulating generation of inositol 1,4,5-triphosphate in brain synaptosomes, 814-817
Cerebral blood vessels, livedo racemosa, nephropathy, and occlusion of, in Sneddon's syndrome, 511-515
CES (cholesterol embolization syndrome), streptokinase and, ARF and, 508-510
Charges for vascular access in ESRD, *see* Allowed charges for vascular access in ESRD, USRDS 1995 ADR on
Chemoattractant signals in obstructive nephropathy, 134-135
Chemokines, renal disease and, 982-994
  C-C chemokines, 984, 986-987
  conclusions and perspectives on, 990-991
  C-X-C chemokines, 983-985
  historical background, properties, and receptors for, 983-984
  MCP-1 chemokines, 984-990
  RANTES chemokines, 987-988
Children, *see entries beginning with term*: Pediatric
Chimerism, and DST effects, 710
Chloride, *see* Cl
Cholesterol
  and diet-induced hypercholesterolemia, glomerular injury due to, 152-161
  high-density lipoprotein-, *see* High-density lipoprotein-cholesterol
  levels of, and survival on PD and HD, 221, 223, 224
  low-density lipoprotein-, *see* Low-density lipoprotein-cholesterol
  plasma, in NS, 183
  serum, *see* Serum cholesterol
  total, *see* Total cholesterol
Cholesterol embolization syndrome (CES), streptokinase and, ARF and, 508-510
Chromosomal translocation in posttransplant lymphoproliferative disorder due to EBV of donor origin, 84-87
Chronic hemodialysis (HD)
  idiopathic dialysis ascites in, 668-670
  SRA for, indications for, and prognosis with, 602-606
  see also Continuous ambulatory peritoneal dialysis; Maintenance hemodialysis
Chronic intravenous iron (Fe) supplementation, rHuEPO dose with, in ESRD patients on HD, 41-46
Chronic renal allograft rejection, vascular, role of eosinophils in, 634-642
Chronic renal failure (CRF)
  anemia of, *see* Anemia of ESRD or CRF
  circadian variations in BP in, 716-721
  and compulsive water drinking due to anticholinergic drugs, 586-589
  hepatitis B vaccination associated with tetanus immunization in, 454-460
  HIV-associated, apoptosis in, 286-291
  incidence of, following heart-lung transplant, 643-648
  muscle in, *see* Muscle in CRF
  pediatric, metastatic renal cell carcinoma in renal transplant for, with adult cadaveric kidney, 960-962
  renal ablation model of, prevention of disease progression with renal afferent denervation in, 861-865
  SRA in chronic HD for, indications for, and prognosis with, 602-606

see also Uremia
Cilazapril, progression of hypertension and uremia delayed with, in PKD, 942-946
Ciprofloxacin, renal vasculitis associated with, 516-519
Circadian variations in BP, renal function versus, 716-721
Circulating erythropoietin (EPO), efficacy of enalapril for posttransplant erythrocytosis independent of levels of, 495-500
Circulating leukocyte-endothelium interactions in GN, *see* Leukocytes, recruitment of, in GN
Circulating renin-angiotensin system (RAS) during development, 422-423
Cl (chloride)
in ARF patients on HCO_3-based CRRT, 913
levels of, and survival on PD and HD, 221, 223, 224
in severe hypercalcemia with renal failure, 675
Classification of carpotarsal osteolysis with nephropathy, 790
Clinical benefits of rHuEPO, S1:2-5
Clinical features and presentation
of familial FSGS, 34-40
of renal cell carcinoma in ACKD, 3-4
see also specific conditions
Clonal deletion, and effects of DST, 709-710
Clotting
dialyzer, with rhuEPO, S1:12
see also Coagulation
CMA (Case Mix Adequacy) Study, USRDS, S2:172
CO_2 (carbon dioxide) in ARF patients on HCO_3-based CRRT, 913
Coagulation
HD effects on, 614-621
see also Clotting; Thrombosis
COL4A5 gene, splicing mutations of, in Alport's syndrome, 732-739
Colchicine for reactive amyloidosis, 273-274
Collagen
effects of sex hormones on synthesis of, 147-148
in obstructive nephropathy, 141-145
Collapsing glomerulopathy, incidence of, with idiopathic NS, 740-750
Committees, USRDS, S2:6-7, S2:20-22
Comorbidity
with ESRD, USRDS 1995 ADR on, *see* Comorbidity with ESRD, USRDS 1995 ADR on
urea kinetics, appetite and, in CAPD patients, survival and, 353-361
see also specific conditions
Comorbidity with ESRD, USRDS 1995 ADR on
mortality and survival and, S2:81-82
vascular access and, S2:143
Compartmental disequilibrium, dialysis dose and, 974-976
Compensatory growth, and cyst development in ESRD patients, 8-9
Complement (C)
Ancrod effects on, in SLE and DPLN, 538
in renal allograft recipients with MPGN type I, 664
serum, in HIV-associated nephropathy, 448
Complement C1q (C1q), changes in antibodies to, and renal relapses in systemic lupus erythematosus, 595-601
Completeness of USRDS data, S2:175
Complications, *see* Adverse effects; Outcome *specific conditions and treatment modalities*
Compulsive water drinking (psychogenic polydipsia) due to anticholinergic drugs, CRF and, 586-589
Computed tomography (CT) of renal cell carcinoma, 4
Computers needed for SAF use, S2:27
Connective tissue disease (CTD), mixed, recovery from renal infarction in, 649-653
Contamination
touch, and peritonitis on CAPD, 765-773
see also Infection(s)
Continuous ambulatory peritoneal dialysis (CAPD)
for amyloidosis, 277-279
for ARF following streptokinase for acute myocardial infarction, 508-510
dietary protein intake and urea nitrogen appearance on, 969-970
effects of HCO_3- versus lactate-based dialysate on peritoneal macrophage function in, 924-933
peritonitis in, *see* Peritonitis on CAPD
serum PTH levels and bone turnover in, 622-631
SGNA of patients on, 475–486; *see also* Malnutrition on HD and/or CAPD
survival on, *see* Continuous ambulatory peritoneal dialysis, survival on
see also Continuous ambulatory peritoneal dialysis for ESRD
Continuous ambulatory peritoneal dialysis (CAPD), survival on
comorbidity, appetite, Kt/V and, 353-361
malnutrition and, 256-258
markers for, 209-219
Continuous ambulatory peritoneal dialysis (CAPD) for ESRD
for diabetic ESRD, symptomatic hypercalcemia in 831-835
see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1995 ADR on
Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, USRDS 1995 ADR on
international, S2:161-163
as option, S2:52
prescription for, S2:62-63
USRDS study on peritonitis in, S2:171
Continuous cycling ambulatory peritoneal dialysis, USRDS 1995 ADR on, *see* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1995 ADR on
Continuous renal replacement therapy (CRRT)
HCO_3 dialysate for, in ARF patients in ICU, 910-917
see also Chronic hemodialysis; Continuous ambulatory peritoneal dialysis
Continuous ultrasound (US) guidance in percutaneous renal biopsy, outcome and, 580-585
Coordinating Center (CC) of The University of Michigan, S2:5-6
Cortical transforming growth factor-β (TGF-β), expression of, in obstructive nephropathy, 135-136
Cost
of ESRD care, USRDS 1995 ADR on, *see* Cost and cost-effectiveness of ESRD, USRDS 1995 ADR on
of rHuEPO therapy, S1:5-8
of using SAF, S2:27
Cost and cost-effectiveness of ESRD care, USRDS 1995 ADR on, S2:18

analysis of, S2:185-186
see also Medicare expenditures for ESRD, USRDS 1995 ADR on; Vascular access for ESRD, cost and cost-effectiveness of, USRDS 1995 ADR on
C-reactive protein in MPO-ANCA-positive crescentic GN with Graves' disease, 755
Creatinine (Cr) and creatinine (Cr) clearance
Ancrod effects on, in SLE and DPLN, 538
in ARF patients on HCO_3-based CRRT, 913
on CAPD and/or HD, *see* Creatinine and creatinine clearance on CAPD and/or HD
in compulsive water drinking patients, 587
and CsA withdrawal in stable transplant recipients, 490
in familial FSGS, 37
in HIV-associated nephropathy, 289
LCD versus traditional Ca dialysate effects on, 633
in lupus nephritis, 302
in MPO-ANCA-positive crescentic GN with Graves' disease, 755
in NS, 172, 173
serum, *see* Serum creatinine
in severe hypercalcemia with renal failure, 675
and survival on PD, 215, 221, 223, 224
and uninephrectomy in adulthood, 890-892
urinary P/C ratio as predictor of urinary protein excretion in IDDM, 904-909
weekly, and dialysis dose, 977-978
Creatinine (Cr) and creatinine (Cr) clearance on CAPD and/or HD
predialysis Cr in uremic HD patients with sleep complaints, 752
rhGH therapy of malnutrition and, 263
survival and, 215, 221, 223, 224, 355, 356
Crescentic glomerulonephritis, *see* Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis
CRF, *see* Chronic renal failure
Critically ill end-stage renal disease (ESRD) patients on HD, vancomycin removal by high-flux polysulfone membranes in, 469-474
Cross-inhibition assays of ANCAs and anti-GBM antibodies in RPGN, 442
Cross-linked hemoglobin (Hb), diaspirin, for HD patients, pharmacokinetics and pharmacodynamics of, 918-923
Cryoglobulin
heat-insoluble, in essential cryoglobulinemia type I and massive cryoglobulinemic-occlusive GN, 654-657
serum, in renal allograft recipients with MPGN type I, 664
Cryoglobulinemia, essential type I, heat-insoluble cryoglobulin in, 654-657
Cryoglobulinemic-occlusive glomerulonephritis (GN), massive, heat-insoluble cryoglobulin in, 654-657
CsA, *see* Cyclosporin A
CT (computed tomography) of renal cell carcinoma, 4
CTD (connective tissue disease), mixed, recovery from renal infarction in, 649-653
CTH (trihexosylceramide), accumulation of renal, in Fabry's disease, 952-955
Current studies, USRDS, S2:167-169
Cutaneous infection, *A elegans*, in renal transplant recipients, 381-384
C-X-C chemokines, renal disease and, 983-985
Cyclic adenosine monophosphate (cAMP), as mediator in Pi transport inhibition by KW-3902, 825-830
Cycling peritoneal dialysis, continuous, USRDS 1995 ADR on, *see* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1995 ADR on
Cyclosporin A (CsA)
and incidence of CRF following heart-lung transplant, 643-648
role of lipids, hypertension and, in progressive renal insufficiency following cardiac transplantation, 193-201
withdrawal from, *see* Withdrawal from CsA
Cystic disease
in Medicare ESRD patients, S2:33
see also Polycystic kidney disease
Cytokines, *see* Chemokines, renal disease and *and specific cytokines*
Cytoplasmic antibodies, *see* Antineutrophil cytoplasmic antibody(ies)
Cytosolic Ca (calcium), and PTH stimulating generation of phosphoinositol in brain synaptosomes, 814-817

DA (disinfectant agent) release, rinsing time of reused dialyzers and, 549-553
Data, USRDS
access to, S2:173
acknowledging use of, S2:25
completeness of, S2:175
new, S2:174-177
release of, S2:28-29
requests for, S2:24-25
USRDS research studies on existing, S2:172-173
see also United States Renal Data System
Data Request Review Committee (DRRC), USRDS, S2:7
Data Validation Study, USRDS, S2:170
Database, USRDS, S2:22-23
see also Data, USRDS
DBM infusion, *see* Donor bone marrow infusion
DCLHb (diaspirin cross-linked hemoglobin) for HD patients, pharmacokinetics and pharmacodynamics of, 918-923
Death, *see* Mortality
Death Notification Form, S2:174, S2:177
Deletion/insertion polymorphism of angiotensin I-converting enzyme gene, with IgAN, 727-731
Delivered Kt/V, prescribed versus, 977
Denervation, renal afferent, prevention of renal disease progression with, in renal ablation model of CRF, 861-865
Deoxyribonucleic acid, *see* Double-stranded DNA
Department of Veterans Affairs (DVA) report on ESRD care facilities, S2:158-160
Desirable body weight (BW), defined, urea kinetics and, 965-966
Development, *see* Growth and development
Diabetes mellitus, *see* Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus *and entries beginning with term*: Diabetic
Diabetic end-stage renal disease (ESRD)
serum PTH levels and bone turnover and, 626
symptomatic hypercalcemia in CAPD patients with, 831-835

vascular access thrombosis and, 342
see also Diabetic end-stage renal disease, USRDS 1995 ADR on
Diabetic end-stage renal disease (ESRD), USRDS 1995 ADR on
Medicare and non-Medicare patients, S2:33, S2:35
treatment incidence and, S2:43, S2:44
vascular access type and, S2:144
Diabetic gastroenteropathy, renal function deterioration secondary to oxalate deposition in, 68-71
Diabetic macular edema, rHuEPO in renal insufficiency and, 202-208
Diabetic nephropathy
acquired oligonephropathy and, 898-903
AGE products effects in, 880-881; *see also* Advanced glycosylation end products in diabetic nephropathy and diabetic vascular disease
cellular hypoxia in, 202-208
circadian variations in BP in, 719
hypertensive, *see* Hypertensive diabetic nephropathy
and peritonitis on APD and CAPD, 48
in renal transplant patients, CsA withdrawal and, 489
and survival, *see* Diabetic nephropathy, survival and
and vascular access thrombosis, 342
see also Diabetic end-stage renal disease
Diabetic nephropathy, survival and
on CAPD, 213-215
on PD, 221
Diabetic retinopathy, pseudohypoxia and, 202-208
Diabetic vascular disease, *see* Advanced glycosylation end products in diabetic nephropathy and diabetic vascular disease
Diagnosis
of amyloidosis, 268-270; *see also* Radiolabeled serum amyloid P scintigraphy of amyloidosis
ESRD, USRDS 1995 ADR on, S2:143
of Fe deficiency anemia following rHuEPO therapy in CRF, 292-299
primary, *see* Primary disease
of renal cell carcinoma in ACKD, 4
see also Evaluation *specific diagnostic techniques; for example*: Bone biopsy *and specific conditions*
Dialysate
traditional versus low calcium, and peritonitis rate, 632-633
see also HCO_3-based dialysate; Lactate-based dialysate
Dialysis
for ARF, 570-571
and cyst development in ESRD patients, 8
see also Dialysis dose; Dialysis membranes; Dialytic removal; Dialyzers; Hemodialysis; Parathyroid hormone, Ca, P and, in dialysis patients; Peritoneal dialysis; Renal replacement therapy
Dialysis dose
effects of, on malnutrition on HD and/or CAPD, 259-260
urea kinetics and estimation of, 971-978
see also Kt/V
Dialysis membranes
effects of, on malnutrition on HD and/or CAPD, 259-260
high-flux polysulfone, for vancomycin removal in critically ill ESRD patients on HD, 469-474
see also Biocompatible membranes
Dialysis Morbidity and Mortality Study (DMMS), S2:167-169
Dialytic removal
of iron dextran by HD, 327-330
of K in hyperkalemia of ESRD, albuterol effects on, 607-613
of vancomycin with high-flux polysulfone membranes in critically ill ESRD patients on HD, 469-474
Dialyzers
clotting of, with rHuEPO, S1:12
effects of, on ACA concentration, 349
reused, rinsing time and release of formaldehyde, hypochlorite, warexin, and renalin, 549-553
Diaspirin cross-linked hemoglobin (DCLHb) in HD patients, pharmacokinetics and pharmacodynamics of, 918-923
Diastolic blood pressure, *see* Blood pressure
Dietary cholesterol, glomerular injury induced by, 152-161
Dietary diaries in estimation of dietary protein intake, 967
Dietary protein
in CRF, metabolic responses to, 243-244
intake of, and urea kinetics, 967-971
requirements in, and malnutrition on HD and/or CAPD, 229-230; *see also* Malnutrition on HD and/or CAPD
Differential diagnosis of symptomatic hypercalcemia in diabetic ESRD patients on CAPD, 832
Diffuse proliferative lupus nephritis (DPLN), glomerular thrombosis and, 535-540
1,3-Dipropyl-8-(3-noradamantyl)xanthine (KW-3902) inhibiting Pi transport, cAMP as mediator in, 825-830
Disinfectant agent (DA) release, rinsing time of reused dialyzers and, 549-553
Disordered breathing events during sleep of uremic HD patients, 753, 755
Diuretics in ARF therapy, 567-569
DM (diabetes mellitus), *see* Non-insulin-dependent diabetes mellitus *and entries beginning with term*: Diabetic
DMMS (Dialysis Morbidity and Mortality Study), S2:167-169
DNA (deoxyribonucleic acid), *see* Double-stranded DNA; Polymorphism
Documentation, SAF, S2:27
Donor(s)
posttransplant lymphoproliferative disorder due to EBV infection of donor origin, 84-87
see also Cadaveric renal graft; Donor-specific transfusion; Living donors *and specific types of transplantation*
Donor bone marrow (DBM) infusion, 706-710
mechanisms of immunomodulation from, 708-710
Donor-specific transfusion (DST), 701-715
DBM infusion and, *see* Donor bone marrow infusion
effects of, on T cells, *see* T cells, DST effects on
history of, 704
mechanisms of immunomodulation from, 708-710
sensitization and, 705-706
variables determining efficacy of, 706
at Washington University/Barnes Hospital, 704-705
Dopamine
in ARF therapy, 568, 569
low-dose, rIL-2-induced ARF in cancer patients reversed with infusions of, 27-33

Doppler echocardiography of calcific mitral stenosis in ESRD, 956-959
Dose
  dialysis, *see* Dialysis dose
  of IV calcitriol in dialysis patients with severe HPHT, 845-851
  rHuEPO, *see* Dose, rHuEPO
  see also entries beginning with terms: Low-dose
Dose, rHuEPO
  with chronic intravenous iron supplementation, 41-46
  effects of L-carnitine and, on anemia, 758-759
  hypertension and, 463
  optimal, S1:5-8
Double-stranded DNA (dsDNA)
  Ancrod effects on, in SLE and DPLN, 538
  changes in antibodies to, and renal relapses in systemic lupus erythematosus, 595-601
DPLN (diffuse proliferative lupus nephritis), glomerular thrombosis and, 535-540
DRRC (Data Request Review Committee), USRDS, S2:7
Dry body weight (BW), defined, urea kinetics and, 964
dsDNA, *see* Double-stranded DNA
DST, *see* Donor-specific transfusion
Duration of CAPD and/or HD
  of chronic HD, SRA and, 603
  for ESRD, *see* Duration of CAPD and/or HD for ESRD
  sleep complaints and, in uremic patients, 752
Duration of CAPD and/or HD for ESRD
  and hypertension and, 323, 463
  malnutrition and, 478
  peritonitis and, 48
  serum PTH levels and bone turnover and, 626
  and TCC associated with ACKD, 9
  see also Duration of CAPD and/or HD for ESRD, rHuEPO and
Duration of CAPD and/or HD for ESRD, rHuEPO and, 332
  and chronic intravenous Fe and, 42
DVA (Department of Veterans Affairs) report on ESRD care facilities, S2:158-160

EAA (essential amino acid) supplementation in ARF therapy, 572-573
Early dialysis for ARF, 570-571
EBV (Epstein-Barr virus) of donor origin, posttransplant lymphoproliferative disorder due to, 84-87
EC (Executive Committee), USRDS, S2:6
Echocardiography, *see* Ultrasound
ECM (extracellular matrix) proteins, long-lived, AGE products effects on, 877-878
Economic Scientific Advisory Committee (E-SAC), USRDS, S2:6-7
Edema
  diabetic macular, rHuEPO in renal insufficiency and, 202-208
  edema-free body weight defined, urea kinetics and, 964
EDRF/NO (endothelium-derived relaxation factor/nitric oxide; nitric oxide), ET-1 and ET-3 interactions with, 116-123
Educational level, and peritonitis on APD and CAPD, 49-51
Efficacy of DST, variables affecting, 706
Eligibility
  criteria of, for alternate-day prednisone and fish oil supplementation in IgA nephropathy, 793-794
  to Medicare ESRD program, S2:176
Embryonic epithelial-mesenchymal transformation, 679-683
  activation of epithelial programs in definitive embryonic mesenchyme, 681-683
Enalapril for erythrocytosis following renal transplantation, 495-500
Endocrinology, origins of, 801-803
Endothelial interactions with circulating leukocytes, *see* Leukocytes, recruitment of, in GN
Endothelin-1 (ET-1)
  albumin, IgG, and transferrin effects on synthesis and secretion of proximal tubular cell, 934-941
  interactions of, with prostaglandins and nitric oxide, 116-123
Endothelin-3 (ET-3), interactions of, with prostaglandins and nitric oxide, 116-123
Endothelium-derived relaxation factor/nitric oxide (nitric oxide; EDRF/NO), ET-1 and ET-3 interactions with, 116-123
End-stage renal disease
  calcific mitral stenosis in, progression of, 956-959
  see also Chronic renal failure; Diabetic end-stage renal disease; Hemodialysis for ESRD; Recombinant human erythropoietin for ESRD (and/or CRF); United States Renal Data System
Energy intake
  by hypertensive diabetic nephropathy patients, 100
  low, and malnutrition on HD and/or CAPD, 234
Energy requirements on HD and CAPD, malnutrition and, 229-230
Enteral nutrition
  proposed HCFA guidelines for reimbursement of, 995-997
  see also Parenteral nutrition
Eosinophils
  infiltration of, in NS with triazolam-induced AIN, 62-67
  role of, in chronic vascular rejection of renal allografts, 634-642
Epifluorescence microscopy of chronic vascular rejection of renal allografts, 634-642
Epithelial-mesenchymal transformation, 678-689
EPO, *see* Erythropoietin
Epoietin alfa, *see* Recombinant human erythropoietin
Epstein-Barr virus (EBV) of donor origin, posttransplant lymphoproliferative disorder due to, 84-87
Erythrocyte (red blood cell) urinary casts, white blood cell and, relationship between onset of relapse of SLE and, 432-438
Erythrocytosis following renal transplantation, enalapril for, 495-500
Erythropoietin (EPO)
  circulating, efficacy of enalapril for posttransplant erythrocytosis independent of levels of, 495-500
  in uremic HD patients on with sleep complaints, 752
  see also Recombinant human erythropoietin
E-SAC (Economic Scientific Advisory Committee), USRDS, S2:6-7
ESRD (end-stage renal disease), *see* Chronic renal failure; Diabetic end-stage renal disease; Hemodialysis for ESRD; Recombinant human erythropoietin for ESRD (and/or CRF); United States Renal Data System

Essential amino acid (EAA) supplementation in ARF therapy, 572-573
Essential hypertension, nephron number at birth and, 91-98
Essential type I cryoglobulinemia, heat-insoluble cryoglobulin in, 654-657
Estimated Medicare expenditures for ESRD, 1992, USRDS 1995 ADR on, S2:152
Estimated Medicare reimbursements for vascular access in ESRD, USRDS 1995 ADR on, S2:148
Estrogens
  effects of, on mesangial cells, 147-151
  effects of low-dose transdermal, on BT and bleeding in uremia, 22-26
ET-1, *see* Endothelin-1
ET-3 (endothelin-3), interactions of, with prostaglandins and nitric oxide, 116-123
Ethics of living kidney donation, 388-390
Evaluation
  SGNA of HD and CAPD patients, 475-486
  of unrelated living donors, 390
  see also Diagnosis; Living related donors, evaluation and selection of
Exclusion
  from alternate-day prednisone and fish oil supplementation program in IgA nephropathy, 794
  of living kidney donors, criteria for, 394-395
Executive Committee (EC), USRDS, S2:6
Existing data studies, USRDS 1995 ADR on, S2:172-173
Expected remaining years in ESRD, USRDS 1995 ADR on, S2:82-83, S2:183
Expenditures, *see* Cost; Medicare expenditures for ESRD, USRDS 1995 ADR on
Extracellular matrix (ECM) proteins, long-lived, AGE products effects on, 877-878
Extrarenal manifestations of lupus nephritis, 301

Fabry's disease, renal CTH accumulation in, 952-955
Facilities for ESRD care, USRDS 1995 ADR on, S2:18, S2:157-166
  described, S2:157-158
  DVA report on, S2:158-160
  number and location of, S2:157
Familial amyloid polyneuropathy, treatment of, 279-280
Familial focal segmental glomerulosclerosis (FSGS), clinical and pathologic features of, 34-40
Familial hypertension, history of, and follow-up on patients having undergone uninephrectomy in adulthood, 889-897
Familial renal disease
  screening living kidney donors for, 393-394
  see also entries beginning with term: Familial
Fasting plasma glucose in NIDDM patients, GFR and, 724
Fe, *see* Iron; Iron deficiency
Females
  heterozygous, with Fabry's disease and renal CTH accumulation, 952-955
  see also Sex
Ferritin
  L-carnitine and rHuEPO therapy effects on, 761
  levels of, and survival on PD and HD, 221, 223, 224
  serum, in Fe deficiency anemia following rHuEPO therapy, 292-299
FGS (focal glomerulosclerosis), idiopathic HIV-associated, apoptosis in, 286-291
Fibrinogen
  Ancrod effects on, in SLE and DPLN, 538
  in RPGN, 14
Fibroblasts, different expression of mRNA between leukocytes and, in Alport's syndrome, 732-739
Fibrosis, *see* Interstitial fibrosis
"Fifteen month rule", S2:176-177
Files, SAF, S2:27
Fine needle aspiration biopsy of renal cell carcinoma, 4
Fish oil supplementation, alternate-day prednisone and, in young IgAN patients, 792-796
Focal glomerulosclerosis (FGS), idiopathic HIV-associated, apoptosis in, 286-291
Focal segmental glomerulosclerosis (FSGS)
  in adult idiopathic NS, 740-750
  familial, clinical and pathologic features of, 34-40
  lung transplantation and, 527-531
Follow-up
  on kidney donors, 396
  on patients uninephrectomized in adulthood, 889-897
Formaldehyde, rinsing time of reused dialyzers and release of, 549-553
Format, SAF, S2:27
Free secretory component (FSC), urinary excretion of sIgA and, in pyelonephritis, 590-594
FSGS, *see* Focal segmental glomerulosclerosis
Furosemide in ARF therapy, 567-569

Gallium scan in interstitial nephritis with sarcoidosis, 947-951
Gastroenteropathy, diabetic, renal function deterioration secondary to oxalate deposition in, 68-71
Gastrointestinal function, recovery of, after renal transplantation in patient with sclerosing peritonitis secondary to CAPD, 658-661
Gender, *see* Sex
Gene(s), 727-739
  angiotensin I-converting enzyme, insertion/deletion polymorphism in, with IgAN, 727-731
  COL4A5, splicing mutations in, in Alport's syndrome, 732-739
  promoting epithelial-mesenchymal transformation, 686
  RAS, expression of, 416-421
General population
  effects of IGF-1 on renal handling of P, Ca, and Na in, 818-824
  renal cell carcinoma in, 2
Genotype
  distribution of, of I/D polymorphism in angiotensin 1-converting enzyme, 729
  thrifty genotype hypothesis of nephron supply, 94-95
Geography in USRDS 1995 ADR, S2:177
GF(s) (growth factors), *see* Hepatocyte growth factor/scatter factor; Transforming growth factor-β in obstructive nephropathy *and entries beginning with terms*: Insulin-like growth factor

GFR, *see* Glomerular filtration rate
GH (growth hormone), recombinant human, for malnutrition on HD and/or CAPD, 261-263
Giant cells, multinucleated, IL-6 in antiglomerular basement membrane antibody-induced GN with, 72-79
Globular osmotic fragility, L-carnitine and rHuEPO therapy effects on, 759, 760
Glomerular disease, *see specific conditions*
Glomerular filtration rate (GFR)
  in hypertensive diabetic nephropathy, ACE inhibitor effects on, 99-107
  in Koreans with NIDDM, 722-726
  and malnutrition on CAPD and HD, 478
  see also Hyperfiltration
Glomerular hyperfiltration in Koreans with NIDDM, 722-726
Glomerular injury
  in dietary cholesterol-induced hypercholesterolemia, 152-161
  see also specific types of glomerular injuries
Glomerular macrophages
  in glomerular injury with dietary cholesterol-induced hypercholesterolemia, 152-161
  in GN, activation of, to oxidize low-density lipoproteins, 362-367
Glomerular thrombosis, and progression of GN, 535-540
Glomerulomegaly, lung transplantation and, 527-531
Glomerulonephritis (GN)
  ANCA-positive crescentic, *see* Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis
  antiglomerular basement membrane antibody-induced, with multinucleated giant cells, IL-6 in, 72-79
  chemokines in, *see* Chemokines, renal disease and
  in ESRD, *see* Glomerulonephritis in ESRD, USRDS 1995 ADR on
  glomerular macrophages in, activation of, to oxidize low-density lipoproteins, 362-367
  glomerular thrombosis and progression of, 535-540
  IgA, *see* IgA nephropathy
  immune complex-mediated, as HIV-associated nephropathy, 446-453
  massive cryoglobulinemic-occlusive, heat-insoluble cryoglobulin in, 654-657
  membranoproliferative type I, in renal allograft, HCV infection and, 662-667
  rapidly progressive, *see* Rapidly progressive glomerulonephritis
  role of tubulointerstitial damage in, in renal disease progression, 124-132
  see also Leukocytes, recruitment of, in GN *and specific types of glomerulonephritis*
Glomerulonephritis (GN) in ESRD, USRDS 1995 ADR on
  Medicare and non-Medicare ESRD patients, S2:33, S2:35
  treatment incidence and, S2:44-46
  vascular access type and, S2:144
Glomerulosclerosis (GS)
  focal segmental, *see* Focal segmental glomerulosclerosis
  idiopathic HIV-associated focal, apoptosis in, 286-291
Glossary of urea kinetics, *see* Urea kinetics
Glucocorticoids, and proteolytic responses to metabolic acidosis, 244
Glucose
  in ARF patients on HCO_3-based CRRT, 913
  fasting plasma, in NIDDM, 724
  on HD and CAPD, *see* Glucose, malnutrition on HD and CAPD and
  in severe hypercalcemia with renal failure, 675
Glucose, malnutrition on HD and CAPD and, 482
  loss of glucose, 237
Glycosylated Hb (hemoglobin)
  in hypertensive patients with microalbuminuria, 578
  in NIDDM, 724
Glycosylation end products, advanced, *see* Advanced glycosylation end products in diabetic nephropathy and diabetic vascular disease
GN, *see* Glomerulonephritis
Graft, *see* Polytetrafluoroethylene grafts in HD; Renal allograft *and specific types of transplantation*
Granulomatous interstitial nephritis (IN) with sarcoidosis, multiorgan involvement in, 947-951
Graves' disease with MPO-ANCA-positive crescentic GN, complications in, 774-780
Gross features of renal cell carcinoma, 6
Growth and development
  intrauterine growth retardation and essential hypertension, 94
  see also Growth and development of ESRD patients; Renin-angiotensin system during development
Growth and development of ESRD patients
  cyst development and compensatory growth, 8-9
  see also Growth and development of pediatric ESRD patients, USRDS 1995 ADR on
Growth and development of pediatric ESRD patients, USRDS 1995 ADR on
  RRT and, S2:125
  USRDS research study on, S2:171-172
Growth factors, *see* Hepatocyte growth factor/scatter factor; Transforming growth factor-β in obstructive nephropathy *and entries beginning with terms*: Insulin-like growth factor
Growth hormone (GH), recombinant human, for malnutrition on HD and/or CAPD, 261-263
GS, *see* Glomerulosclerosis

Haptoglobin, enalapril effects on, 497
Hb (hemoglobin)
  diaspirin cross-linked, in HD patients, pharmacokinetics and pharmacodynamics of, 918-923
  glycosylated, *see* Glycosylated Hb
  LCD versus traditional Ca dialysate effects on, 633
  in MPO-ANCA-positive crescentic GN with Graves' disease, 775
  in uremic HD patients with sleep complaints, 752
  see also Hb, rHuEPO and; HbA_{1c}
Hb (hemoglobin), rHuEPO and
  and Fe deficiency anemia following rHuEPO therapy, 295
  target Hb with rHuEPO therapy, S1:7-8
HbA_{1c} (hemoglobin A_{1c}) in acquired oligonephropathy patients, 899
HCFA, *see* Health Care Financing Administration
HCO_3 (bicarbonate)
  plasma, effects of albuterol on, 610
  in severe hypercalcemia with renal failure, 675

see also HCO_3-based dialysate
HCO_3 (bicarbonate)-based dialysate
for CRRT in ARF patients in ICU, 910-917
effects of lactate- versus, on peritoneal macrophage function in CAPD, 924-933
Hct, *see* Hematocrit
HCV (hepatitis C virus) infection, MPGN type I in renal allograft associated with, 662-667
HD, *see* Hemodialysis
Health Care Financing Administration (HCFA), S2:5
proposed guidelines of, for reimbursement of enteral and parenteral nutrition, 995-997
Heart
PTH action on, 811
see also Heart rate; Heart transplantation *entries beginning with terms*: Myocardial, Ventricular *and element*: Card-
Heart rate
albuterol effects on, 610
and circadian BP variations, 717
Heart transplantation
incidence of CRF following heart-lung transplantation, 643-648
progressive renal insufficiency following, role of CAS, lipids, and hypertension in, 193-201
Heat-insoluble cryoglobulin in essential type I cryoglobulinemia and massive cryoglobulinemic-occlusive GN, 654-657
Height of ESRD patients, S2:35
vascular access type and, S2:144
Hematocrit (Hct)
rHuEPO effects on, *see* Hematocrit, rHuEPO effects on
in severe hypercalcemia with renal failure, 675
and survival on PD and HD, 221, 223
and vascular access thrombosis in ESRD patients on HD, 343-344
Hematocrit (Hct), rHuEPO effects on, 203
L-carnitine and, 759, 761
with intravenous Fe, 43, 45
of SC and/or IV rHuEPO, 335
USRDS 1995 ADR on, S2:184
Hematopoiesis, PTH action on, 811
Hematuria in HIV-associated nephropathy, 448
Hemodialysis (HD)
chronic, *see* Chronic hemodialysis
dietary protein intake and urea nitrogen appearance on, 969-970
effects of, on platelet deposition on native vein fistulas, 614-621
for ESRD, *see* Hemodialysis for ESRD
hepatitis B vaccination associated with tetanus immunization in CRF patients on, 454-460
infection of subclavian venous stent in, 377-380
iron deficiency and iron dextran removal by, 327-330
Kt/V on, 973, 975-976
long-term, for carpotarsal osteolysis with nephropathy, 788-791
maintenance, *see* Maintenance hemodialysis
pharmacodynamics and pharmacokinetics of DCLHb in patients on, 918-923
PTFE grafts in, *see* Polytetrafluoroethylene grafts in HD
SGNA of patients on, 475–486; *see also* Malnutrition on HD and/or CAPD
for SLE, hepatic infarction in, 785-787
sleep complaints in patients on, 751-756
survival on, *see* Hemodialysis, survival on
Hemodialysis (HD), survival on, 209-228
malnutrition and, 256-258
markers of, 209-219
and on PD, compared, 220-228
Hemodialysis (HD) for ESRD
albuterol effects on dialytic K removal in hyperkalemia of ESRD, 607-613
for critically ill ESRD patients, vancomycin removal with high-flux polysulfone membranes in, 469-474
hypertensive, *see* Hypertensive end-stage renal disease in HD patients
β_2M amyloidosis related to, treatment of, 277-279
rHuEPO and, *see* Recombinant human erythropoietin for ESRD (and/or CRF)
serum PTH levels and bone turnover in, 622-631
see also Hemodialysis for ESRD, USRDS 1995 ADR on
Hemodialysis (HD) for ESRD, mortality with, USRDS 1995 ADR on
causes of death, S2:88-91
mortality rate, S2:77-78, S2:80
and withdrawal from HD, S2:91-93
Hemodialysis (HD) for ESRD, USRDS 1995 ADR on
as option, S2:52
prescription for, S2:60-63
see also Hemodialysis for ESRD, mortality with, USRDS 1995 ADR on
Hemodynamic actions of RAS during development, 423-424
Hemoglobin, *see* Hb
Hemoglobinopathies, as adverse effect of rHuEPO, S1:14
Hemolysis, as adverse effect of rHuEPO, S1:14
Hemostatic effects of PTH, 806-807
Hepatic infarction in SLE patients on HD, 785-787
Hepatitis B surface antigen in HIV-associated nephropathy, 448
Hepatitis B vaccination associated with tetanus immunization in CRF, 454-460
Hepatitis C virus (HCV) infection, MPGN type I in renal allograft associated with, 662-667
Hepatocyte growth factor/scatter factor (HGF/SC) in embryonic epithelial-mesenchymal transformation, 681
Hereditary amyloidosis, treatment of, 279-280
Hereditary analbuminemia in NS, 178-186
Heterozygous females with Fabry's disease and renal CTH accumulation, 952-955
HGF/SC (hepatocyte growth factor/scatter factor) in embryonic epithelial-mesenchymal transformation, 681
High-density lipoprotein-cholesterol
L-carnitine and rHuEPO therapy effects on, 761
and malnutrition on CAPD and HD, 482
in NS, 172, 173
High-flux polysulfone membranes in vancomycin removal in critically ill ESRD patients on HD, 469-474
Histogenesis of renal cell carcinoma, 7
Histology and histopathology
of apoptosis in HIV-associated nephropathy, 287-288
of HIV-associated ICGN, 447, 449

of lupus nephritis, 302
of SLE, 537
see also Renal biopsy
Histomorphometry, bone, relationship between intact PTH and, in dialysis patients without aluminum toxicity, 836-844
History
of chemokines, 983-984
of DST, 704
family, of hypertension, and follow-up on patients having undergone uninephrectomy in adulthood, 889-891
see also Natural history; Parathyroid glands, history of
HIV (human immunodeficiency virus)-associated nephropathy
apoptosis in, 286-291
immune complex-mediated GN as, 446-453
HLA (human leukocyte antigen)
DST and, 709
see also HLA matching for renal transplantation
HLA (human leukocyte antigen) matching for renal transplantation
CsA withdrawal and, 489
in ESRD, USRDS 1995 ADR on, S2:101-102
Hospital Standard Analysis File (SAF), S2:26
Hospitalization for ESRD, USRDS 1995 ADR on, S2:17, S2:129-139
analysis of, S2:184-185
SHR and, S2:133-139
trends in, S2:129-133
Host defense mechanisms, effects of CAPD on, peritonitis and, 765-773
HPHT, *see* Hyperparathyroidism
Human immunodeficiency virus, *see* HIV-associated nephropathy
Human leukocyte antigen, *see* HLA
Hydronephrosis, progression of renal disease and, 133-140
Hyperalimentation (total parenteral nutrition), and recovery of gastrointestinal function after renal transplantation in patient with sclerosing peritonitis secondary to CAPD, 658-661
Hypercalcemia
calcitriol in, *see* Calcitriol in hypercalcemia
severe, renal failure and, 674-677
symptomatic, in diabetic ESRD patients on CAPD, 831-835
Hypercholesterolemia, diet-induced, glomerular injury and, 152-161
Hyperfiltration
glomerular, in acquired oligonephropathy with diabetic nephropathy, 898-903
in NIDDM, 722-726
Hyperkalemia in ESRD, effects of albuterol therapy on dialytic K removal in, 607-613
Hyperparathyroidism (HPHT)
and resistance to rHuEPO, S1:12-13
secondary, in uremia, 19-nor-1,25$(OH)_2D_2$ for, 852-860
severe, IV calcitriol dosing in dialysis patients with, 845-851
Hyperphosphatemia in severe HPHT, 845-851
Hypersensitivity reaction, triazolam-induced AIN as, 62-67
Hypertension, 187-201
as adverse effect of rHuEPO, S1:9-11
cilazapril delaying progression of uremia and, in PKD, 942-946
and circadian variations in BP, 716-721
in compulsive water drinking patients, 587
with familial FSGS, 37
history of familial, and status of patients who underwent uninephrectomy in adulthood, 889-897
in IgAN, 728
intrarenal, in acquired oligonephropathy with diabetic nephropathy, 898-903
in lupus nephritis, 302
malignant, in Sneddon's syndrome, 368-372
microalbuminuria in, racial differences in prevalence of, 577-579
and proteinuria, as risk factors for pregnancy-related decline in renal function in primary glomerular disease, 187-192
renal afferent denervation effects on, 861-865
role of CsA, lipids and, in progressive renal insufficiency following cardiac transplantation, 193-201
see also Hypertensive diabetic nephropathy
Hypertensive diabetic nephropathy, 91-107
ACE inhibitors for, 99-107
nephron number at birth, essential hypertension and, 91-98
see also entries beginning with terms: Hypertensive end-stage renal disease
Hypertensive end-stage renal disease (ESRD), USRDS 1995 ADR on
Medicare and non-Medicare ESRD patients, S2:33, S2:35
treatment incidence and, S2:43-45
vascular access type and, S2:144
Hypertensive end-stage renal disease (ESRD) in HD patients
acute serum K decrease and, 321-326
effects of antihypertensive agents on, 461-468
Hypochlorite, rinsing time of reused dialyzers and release of, 549-553
Hypoxia, cellular, in diabetes, 202-208

ICGN (immune complex-mediated glomerulonephritis), HIV-associated, 446-453
ICU (intensive care unit), HCO_3-based as dialysate for CRRT in ARF patients in, 910-917
I/D (insertion/deletion) polymorphism, angiotensin I-converting enzyme gene, with IgAN, 727-731
IDDM, *see* Insulin-dependent diabetes mellitus
Idiopathic dialysis ascites, renal transplantation for, 668-670
Idiopathic focal glomerulosclerosis (FGS), HIV-associated, apoptosis in, 286-291
Idiopathic livedo reticularis, *see* Sneddon's syndrome, as arterio-occlusive disorder
Idiopathic nephrotic syndrome (NS) in adults, incidence of FSGS in, 740-750
IDPN, *see* Intradialytic parenteral nutrition
IDWG (interdialytic weight gain), and hypertensive ESRD, 462, 463
Ig (immunoglobulin) amyloidosis, monoclonal, treatment of, 274-277
IgA (immunoglobulin A)
deficiency in, renal biopsy in identification of, 520-526

secretory, urinary excretion of free secretory component and, in pyelonephritis, 590-594
serum, in HIV-associated nephropathy, 448
see also IgA nephropathy
IgA (immunoglobulin A; Berger's disease) nephropathy (IgAN)
alternate-day fish oil and prednisone supplementation in young patients with, 792-796
insertion/deletion polymorphism of angiotensin I-converting enzyme gene in, 727-731
IgAN, *see* IgA nephropathy
IGF, *see* Insulin-like growth factor 1; Insulin-like growth factor 1 receptors
IgG (immunoglobulin G)
effects of, on synthesis and secretion of proximal tubular cell ET-1, 934-941
in RPGN, 14
serum, in HIV-associated nephropathy, 448
IgM (immunoglobulin M)
in RPGN, 14
serum, in HIV-associated nephropathy, 448
IL, *see entries beginning with term*: Interleukin
Immune complex-mediated glomerulonephritis (ICGN), HIV-associated, 446-453
Immunization, tetanus, associated with hepatitis B vaccination in CRF, 454-460
Immunofluorescence, indirect, of ANCAs and anti-GBM antibodies in RPGN, 441-442
Immunoglobulin, *see entries beginning with acronym*: Ig
Immunomodulation from DST, mechanisms of, 708-710
Immunophenotyping of interstitial mononuclear leukocytes and tubular cells in GN, 124-126
Immunosuppression
and recovery of gastrointestinal function after renal transplantation in patient with sclerosing peritonitis secondary to CAPD, 658-661
see also Cyclosporin A
IN, *see* Interstitial nephritis
Incidence
of CRF following heart-lung transplantation, 643-648
of FSGS in adult idiopathic NS, 740-750
of renal cell carcinoma in ACKD, 3, 4
of sleep complaints in uremic HD patients, 754-755
see also Incidence of ESRD, USRDS 1995 ADR on *and specific conditions*
Incidence of ESRD, USRDS 1995 ADR on, S2:15
analytical methods to determine, S2:174, S2:177-179
see also Incidence of treated ESRD, USRDS 1995 ADR on, S2:39-50
age and, S2:40-41
ESRD diagnosis and, S2:143
international, S2:161
measuring, S2:39-40
mortality and, S2:73-74
pediatric, S2:112-113
primary disease and, S2:43-48
race and, S2:41-42
sex and, S2:42-43
trends in overall, S2:40
Indications
for SRA, 602-606
see also specific conditions
Indirect immunofluorescence of ANCAs and anti-GBM antibodies in RPGN, 441-442
Infarction
acute myocardial, streptokinase for, ARF following, 508-510
hepatic, in SLE patients on HD, 785-787
renal, in mixed CTD, recovery from, 649-653
Infection(s)
A elegans, in renal transplant recipients, 381-384
BK virus, in renal allografts, renal biopsy of, 671-673
EBV, of donor origin, posttransplant lymphoproliferative disorder due to, 84-87
HCV, MPGN type I in renal allograft associated with, 662-667
HIV, *see* HIV-associated nephropathy
and resistance to rHuEPO, S1:14
subclavian venous stent, on HD, 377-380
see also specific infections
Inflammation
interstitial, in ADPKD, 501-507
and resistance to rHuEPO, S1:14
Influenza-like syndrome, as adverse effect of rHuEPO, S1:12
Inositol 1,4,5-triphosphate (phosphoinositol), PTH stimulating generation of, in brain synaptosomes, 814-817
Insertion/deletion (I/D) polymorphism, angiotensin I-converting enzyme gene, with IgAN, 727-731
Insulin, and albuterol effects on removal dialytic K in hyperkalemia of ESRD, 607-613
Insulin-dependent diabetes mellitus (IDDM; Type I diabetes mellitus)
urinary P/C ratio as predictor of urinary protein excretion in, 904-909
see also entries beginning with term: Diabetic
Insulin-like growth factor 1 (IGF-1)
action of, in skeletal muscle in CRF, 248-255
effects of, on renal handling of P, Ca, and Na in normal population, 818-824
Insulin-like growth factor 1 (IGF-1) receptors, characteristics of, 251-252
Intensive care unit (ICU), HCO_3-based dialysate for CRRT of ARF, 910-917
Intensive dialysis for ARF, 571
Interdialytic weight gain (IDWG), and hypertensive ESRD, 462, 463
Interferon-α therapy of MPGN type I in renal allograft, 662-667
Interleukin-1β (IL-1β) in antiglomerular basement membrane antibody-induced GN with multinucleated giant cells, 74
Interleukin-2 (IL-2), recombinant, low-dose dopamine infusions reversing ARF induced by, in cancer patients, 27-33
Interleukin-6 (IL-6) in antiglomerular basement membrane antibody-induced GN with multinucleated giant cells, 72-79
Interleukin-8 (IL-8), former and alternatives names for, 985
International renal replacement therapy (RRT) modality(ies) for ESRD, USRDS 1995 ADR on, S2:161-166
by dialysis modalities, S2:161-163
incidence of, S2:161

patient survival with, S2:163-165
prevalence of, S2:161, S2:163
renal transplantation as, S2:163
Internet World Wide Web, USRDS on, S2:23
Interstitial fibrosis
in ADPKD, 501-507
in GN, mechanisms linking tubular damage and interstitial mononuclear leukocytes to, 129
see also Obstructive nephropathy, tubulointerstitial fibrosis in, macrophage infiltration and
Interstitial inflammation in ADPKD, 501-507
Interstitial mononuclear leukocytes in GN
immunophenotyping of tubular cells and, 124-126
infiltration of, 128-129
Interstitial nephritis (IN)
acute, triazolam-induced, eosinophilic infiltration in NS with, 62-67
arsenic intoxication associated with tubulointerstitial nephritis, 373-376
ciprofloxacin-associated, 516-519
in sarcoidosis, multiorgan involvement in, 947-951
secondary to oxalate deposition, 68-71
Interviews in estimation of dietary protein intake, 967
Intimal proliferation in Sneddon's syndrome, 368-372
Intoxication
aluminum, *see* Aluminum toxicity
arsenic, with tubulointerstitial nephritis, 373-376
Intradialytic parenteral nutrition (IDPN)
for malnutrition on HD and/or CAPD, 261
proposed HCFA guidelines for reimbursement of, 995-997
Intrarenal hypertension in acquired oligonephropathy with diabetic nephropathy, 898-903
Intrauterine growth retardation, and essential hypertension, 94
Intravenous (IV) calcitriol [1,25$(OH)_2D_2$], dosing of, in dialysis patients with severe HPHT, 845-851
Intravenous (IV) iron (Fe) supplementation, chronic, rHuEPO dose with, in ESRD patients on HD, 41-46
Intravenous (IV) recombinant human erythropoietin (rHuEPO) for HD patients with ESRD, subcutaneous versus, 331-340
Investigator initiated research, policy on release of USRDS data for, S2:28-29
Iron (Fe)
levels of, and survival on PD and HD, 221, 224
see also Iron, rHuEPO and; Iron deficiency
Iron (Fe), rHuEPO and
and L-carnitine, 760, 761
Fe management with rHuEPO, S1:8-9
rHuEPO dose with chronic IV Fe supplementation, 41-46
Iron (Fe) deficiency
anemia due to, following rHuEPO in CRF, diagnosis of, 292-299
and iron dextran removal by HD, 327-330
Iron dextran, removal of, by HD, 327-330
Ischemia, and cyst development in ESRD patients, 8
Ischemic stroke in Sneddon's syndrome, 368-372
Islet cells, PTH action on, 811
IV (intravenous) calcitriol [1,25$(OH)_2D_2$], dosing of, in dialysis patients with severe HPHT, 845-851
IV (intravenous) iron (Fe) supplementation, chronic, rHuEPO dose with, in ESRD patients on HD, 41-46
IV (intravenous) recombinant human erythropoietin (rHuEPO) for HD patients with ESRD, subcutaneous versus, 331-340

K (potassium)
acute water loading and angiotensin II receptor antagonist effects on excretion of, 111
albuterol effects on removal of dialytic, in hyperkalemia of ESRD, 607-613
in ARF patients on HCO_3-based CRRT, 913
L-carnitine and rHuEPO therapy effects on, 761
levels of, and survival on PD and HD, 221
and rhGH therapy of malnutrition on HD and/or CAPD, 263
serum, *see* Serum K
in severe hypercalcemia with renal failure, 675
Kidney supply
USRDS 1995 ADR on, S2:103-105
see also Donor(s)
Kidney weight, dietary cholesterol effects on, 153
Kinetics, *see* Pharmacodynamics (and pharmacokinetics); Urea kinetics
Koreans with NIDDM, hyperfiltration in, 722-726
Kt/V
comorbidity, appetite and, in CAPD patients, survival and, 353-361
and dialyzer clotting with rHuEPO, S1:12
on HD, 973, 975-976
and hypertension due to acute serum K decrease, 323
LCD versus traditional Ca dialysate effects on, 633
on peritoneal dialysis, 977
prescribed versus delivered, 977
see also Dialysis dose
KW-3902 [1,3-dipropyl-8-(3-noradamantyl)xanthine] inhibiting Pi transport, cAMP as mediator in, 825-830

Lactate-based dialysate
in CRRT for ARF patients, 910-917
effects of HCO_3- versus, on peritoneal macrophage function in CAPD, 924-933
Lactic dehydrogenase, enalapril effects on, 497
LCD (low calcium dialysate), traditional Ca dialysate versus, and rate of peritonitis, 632-633
Lean body mass, defined, urea kinetics and, 966
Left ventricular mass (LVM), rHuEPO effects on, S1:8
Leukocytes (white blood cells)
casts of urinary, relationship between onset of renal relapse in SLE and, 432-438
different expression of mRNA between fibroblasts and, in Alport's syndrome, 732-739
effects of HCO_3- versus lactate-based dialysate on function of, in CAPD, 924-933
in MPO-ANCA-positive crescentic GN with Graves' disease, 755
see also entries beginning with term: Leukocyte *and specific types of leukocytes*
Leukocytes (white blood cells), recruitment of, in GN, 541-548
adhesion molecules and PAF in, 544-546
mechanisms of, 543-544
of mononuclear cells, 541-542
of neutrophils, 542-543

Lipids
antioxidant effects of sex hormones on, 148-149
lipid-advanced glycosylation, 881-884
PTH effects on metabolism of, 810
role of CsA, hypertension and, in progressive renal insufficiency following cardiac transplantation, 193-201
see also specific lipids
Lipoprotein (Lp)
and Lp-advanced glycosylation, 881-884
see also High-density lipoprotein-cholesterol; Lipoprotein(a); Low-density lipoprotein
Lipoprotein(a) [Lp(a)], 162-177
lovastatin reducing levels of, in NS, 170-177
in RRT patients, 162-169
Livedo racemosa, cerebral blood vessel occlusion, and nephropathy in Sneddon's syndrome, 511-515
Livedo reticularis, *see* Sneddon's syndrome, as arterio-occlusive disorder
Living donors
unrelated, evaluation and screening of, 390
see also Living related donors, evaluation and selection of
Living related donors, evaluation and selection of, 387-398
criteria used to exclude, 394-395
ethics of living kidney donation and, 388-390
evaluation process, 391-393
and follow-up of donors, 396
graft survival with, in ESRD, USRDS 1995 ADR on, S2:97, S2:183
request for, 390-391
screening for familial renal disease in, 393-394
Location of ESRD care facilities, USRDS 1995 ADR on, S2:157
Long-lived extracellular matrix (ECM) proteins, AGE products effects on, 877-878
Long-term hemodialysis (HD) for carpotarsal osteolysis with nephropathy, 788-791
Long-term outcome, *see* Follow-up
Long-term survival with ESRD, USRDS 1995 ADR on, S2:78-79
Lovastatin
effects of, on Lp(a) in nephrotic syndrome, 170-177
effects of, on PKD, 501-507
Low birth weight, nephron formation, essential hypertension and, 94
Low calcium dialysate (LCD), traditional versus, and rate of peritonitis, 632-633
Low-density lipoprotein
activation of glomerular macrophages in GN to oxidize, 362-367
see also Low-density lipoprotein-cholesterol
Low-density lipoprotein-cholesterol
lovastatin effects on, in NS, 170-177
and malnutrition on CAPD and HD, 482
Low-dose dopamine, rIL-2-induced ARF in cancer patients reversed with infusions of, 27-33
Low-dose transdermal estrogens, effects of, on BT and bleeding in uremia, 22-26
Low energy intake, and malnutrition on HD and/or CAPD, 234
Low nutritional intake, and malnutrition on HD and/or CAPD, 230
Lp, *see* Lipoprotein
Lp(a), *see* Lipoprotein(a)
Lung transplantation
FSGS, proteinuria, glomerulomegaly and, 527-531
heart-lung transplant, incidence of CRF following, 643-648
Lupus anticoagulant
ACAs and, in maintenance HD patients, associated with recurrent AVF thrombosis, 347-352
and hepatic infarction in SLE, 785-787
Lupus nephritis
diffuse proliferative, glomerular thrombosis and, 535-540
outcome of, 300-307
see also Systemic lupus erythematosus
LVM (left ventricular mass), rHuEPO effects on, S1:8
Lymphoproliferative disorder, posttransplant, due to EBV of donor origin, 84-87

β_2M (β_2-microglobulin) amyloidosis, treatment of, 277-279
Macrophage(s), *see* Glomerular macrophages; Obstructive nephropathy, tubulointerstitial fibrosis in, macrophage infiltration and; Peritoneal macrophage function
Macular edema, diabetic, rHuEPO in renal insufficiency and, 202-208
Magnesium (Mg) in ARF patients on HCO_3-based CRRT, 913
Magnetic resonance imaging (MRI) of renal cell carcinoma, 4
Maintenance hemodialysis (HD)
ACA association with recurrent AVF thrombosis in, 347-352
see also Chronic hemodialysis; Continuous ambulatory peritoneal dialysis
Malignancy
low-dose dopamine infusions reversing rIL-2-induced ARF in patients with, 27-33
see also Malignant hypertension; Renal malignancy
Malignant hypertension in Sneddon's syndrome, 368-372
Malnutrition on HD and/or CAPD, 229-241, 256-265
cross-sectional comparison of, 475-486
low nutritional intake and, 230
pathogenesis of, 257-259
prevention or therapy of, 259-263
protein catabolism and, 233-238
protein and energy requirements and, 229-230
survival and, 256-258
uremic anorexia and, 231-233
Mannitol in ARF therapy, 567, 568
MAP (mean arterial pressure), *see* Blood pressure
Mass, left ventricular, rHuEPO effects on, S1:8
Massive cryoglobulinemic-occlusive glomerulonephritis (GN), heat-insoluble cryoglobulin in, 654-657
MCN (minimal change nephropathy), incidence of, with idiopathic NS, 740-750
MCP-1 chemokines, renal disease and, 984-990
MCV, *see* Mean corpuscular volume
Mean arterial pressure, *see* Blood pressure
Mean corpuscular volume (MCV)
enalapril effects on, 497
and Fe deficiency anemia following rHuEPO therapy in CRF, 295

Medicare end-stage renal disease (ESRD) program
acceptance into, S2:177-179
delays in eligibility to, S2:176
patients treated under, S2:30-33
see also Treated end-stage renal disease, USRDS 1995 ADR on *and entries beginning with term*: Medicare
Medicare expenditures for ESRD, USRDS 1995 ADR on, S2:26, S2:151-157
estimated (1992), S2:152
trends in (1987-1992; 1991-1992), S2:152-256
see also Cost and cost-effectiveness of ESRD care, USRDS 1995 ADR on; Medicare reimbursements for vascular access in ESRD, USRDS 1995 ADR on
Medicare reimbursements for vascular access in ESRD, USRDS 1995 ADR on, S2:145
defined, S2:142-143
estimates of, S2:148
Melphalan for monoclonal amyloidosis, 275-276
Membranoproliferative glomerulonephritis (MPGN) type I in renal allograft, HCV infection and, 662-667
Membranous nephropathy (MN), incidence of, with idiopathic NS, 740-750
Mesangial cells, effects of sex hormones on, 147-151
Mesangial matrix, effects of sex hormones on degradation of, 148
Mesenchymal-epithelial transformation, 678-689
Messenger ribonucleic acid (mRNA), different expression of, between leukocytes and fibroblasts in Alport's syndrome, 732-739
Metabolic acidosis
in CRF, muscle loss and, 242-247
and malnutrition on HD and/or CAPD, 234-236
Metabolism
apolipoprotein A-I, effects of oncotic pressure on, in NS, 176-186
carbohydrate and lipid, PTH effects on, 810
Metalloproteinases, tissue inhibitors of, obstructive nephropathy and, 136-139
Metanephric mesenchyme transformation into epithelial nephric tubules, 680-681
Metastatic renal cell carcinoma in pediatric recipient of adult cadaveric kidney, 960-962
Methodology, USRDS, S2:24
see also Analytical methods used in USRDS 1995 ADR
Mg (magnesium) in ARF patients on HCO_3-based CRRT, 913
Microalbuminuria
in hypertension, racial differences in prevalence of, 577-579
in NIDDM, 724
see also Albuminuria; Proteinuria
Microangiopathy, thrombotic, ANCA-positive crescentic GN and, 385-386
β_2-Microglobulin (β_2M) amyloidosis, treatment of, 277-279
Microscopy
of antiglomerular basement membrane antibody-induced GN with multinucleated giant cells, 73-74
epifluorescence, of chronic vascular rejection of renal allografts, 634-642
of renal cell carcinoma, 6-7
see also specific conditions
Minimal change nephropathy (MCN), incidence of, with idiopathic NS, 740-750
Minimal change nephrotic syndrome (NS) after CsA withdrawal in bone marrow transplant recipients, renal biopsy of, 532-534
Minimum aggregation size in USRDS 1995 ADR, S2:174-175
Mitral stenosis, calcific, progression to, in ESRD, 956-959
Mixed connective tissue disease (CTD), recovery from renal infarction in, 649-653
MN (membranous nephropathy), incidence of, with idiopathic NS, 740-750
Monitoring of amyloidosis, 268-270
Monoclonal antibodies, anti-CDH, renal CTH accumulation in Fabry's disease detected with, 952-955
Monoclonal immunoglobulin (Ig) amyloidosis, treatment of, 274-277
Mononuclear leukocytes
in GN, 541-542
see also Interstitial mononuclear leukocytes in GN
Monophosphate, cyclic adenosine, as mediator in Pi transport inhibition by KW-3902, 825-830
Morbidity
on HD and CAPD, malnutrition and, 256-257
U.S. trends in renal disease (1979-1990), 308-320
USRDS DMMS on ESRD, S2:167-169
see also Comorbidity *and specific conditions*
Morphogenesis, *see* Growth and development
Mortality
ESRD, *see* Mortality, ESRD, USRDS 1995 ADR on
lupus nephritis, 303
of uninephrectomized patients in adulthood, 893
U.S. trends in renal disease (1979-1990), 308-320
Mortality, ESRD, cause(s) of, USRDS 1995 ADR on, S2:89, S2:90
analytic methods on, S2:85-86
comorbidity as, S2:81-82
DMMS study on, S2:167-169
in pediatric ESRD, S2:125-127
Mortality, ESRD, USRDS 1995 ADR on, S2:69-82
analytical methods to determine, S2:85-86, S2:174, S2:180-182
causes of, *see* Mortality, ESRD, cause(s) of, USRDS 1995 ADR on
on HD and PD, compared, S2:77-78; *see also* Hemodialysis for ESRD, mortality with, USRDS 1995 ADR on; Peritoneal dialysis for ESRD, mortality with, USRDS 1995 ADR on
rates of, S2:69-77, S2:79-81
with renal transplantation, S2:90-91, S2:182
MPGN (membranoproliferative glomerulonephritis) type I, in renal transplant, HCV infection and, 662-667
MPO, *see* Myeloperoxidase
MRI (magnetic resonance imaging) of renal cell carcinoma, 4
mRNA (messenger ribonucleic acid), different expression of, between leukocytes and fibroblasts in Alport's syndrome, 732-739
Multinucleated giant cells, IL-6 in antiglomerular basement membrane antibody-induced GN with, 72-79
Multiorgan involvement in interstitial nephritis with sarcoidosis, 947-951

Muscle, *see* Muscle in CRF; Skeletal muscle
Muscle in CRF, 242-255
  loss of, metabolic acidosis and, 242-247
Mutations, splicing COL4A5 gene, in Alport's syndrome, 732-739
Myeloperoxidase (MPO)
  Graves' disease with MPO-ANCA-positive crescentic GN, complications in, 774-780
  in RPGN, 13-21, 439-445
Myocardial infarction, acute, streptokinase for, ARF following, 508-510
Myofibroblasts, transformation of, in obstructive nephropathy, 136

N (nitrogen), *see* Urea nitrogen
Na (sodium)
  in ARF patients on HCO_3-based CRRT, 913
  L-carnitine and rHuEPO therapy effects on, 761
  and IGF-1 effects on renal handling of P, Ca and, in normal population, 818-824
  levels of, and survival on PD and HD, 221
  pH effects on transport of, 867
  serum, in compulsive water drinking patients, 587
  in severe hypercalcemia with renal failure, 675
  urinary excretion of, *see* Urinary excretion, Na
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), S2:5
Native arteriovenous fistulas (AVFs), HD effects on platelet deposition in, 614-621
Native kidney, solitary, outcome of percutaneous renal biopsy of, 580-585
Natriuretic peptides in ARF therapy, 568, 570
Natural history
  of GN, 127
  of renal cell carcinoma in ACKD, 7-8
NEAA (nonessential amino acid) supplementation in ARF therapy, 572-573
Nephrectomy
  and acquired oligonephropathy with diabetic nephropathy, 898-803
  uninephrectomy in adulthood, follow-up on, 889-897
Nephric tubules, epithelial, metanephric mesenchyme transformation into, 680-681
Nephritis
  tubulointerstitial, arsenic intoxication associated with, 373-376
  see also Glomerulonephritis; Interstitial nephritis; Lupus nephritis
Nephrogenesis, *see* Growth and development
Nephrons, number of, at birth, essential hypertension and, 91-98
Nephropathy (renal disease)
  carpotarsal osteolysis with, long-term HD for, 788-791
  cerebral blood vessel occlusion, livedo racemosa and, in Sneddon's syndrome, 511-515
  U.S. trends in mortality and morbidity of (1979-1990), 308-320
  see also Chemokines, renal disease and; Progression of renal disease *and specific renal diseases*
Nephrotic syndrome (NS), 170-186
  effects of oncotic pressure on apolipoprotein A-I metabolism in, 178-186
  idiopathic, incidence of FSGS in adult, 740-750
  lovastatin effects on Lp(a) in, 170-177
  minimal change, after CsA withdrawal in bone marrow transplant recipients, renal biopsy of, 532-534
  with triazolam-induced AIN, eosinophilic infiltration with, 62-67
Nervous system, *see* Central nervous system, PTH and
Networks, ESRD, S2:7-8
  incidence and prevalence data by, S2:174
Neutrophils in GN, 542-543
New United States Renal Data system (USRDS) data, S2:174-177
NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), S2:5
NIDDM, *see* Non-insulin-dependent diabetes mellitus
Nidogen in epithelial-mesenchymal transformation, 678-689
Nitric oxide (NO; endothelium-derived relaxation factor/nitric oxide), ET-1 and ET-3 interactions with, 116-123
Nitrogen, *see* Urea nitrogen
NO (nitric oxide; endothelium-derived relaxation factor/nitric oxide), ET-1 and ET-3 interactions with, 116-123
Nonclassical target organs, PTH action on, 809-812
Nonessential amino acid (NEAA) supplementation in ARF therapy, 572-573
Non-insulin-dependent diabetes mellitus
  acquired oligonephropathy and, 898-903
  glomerular hyperfiltration in Koreans with, 722-726
  see also entries beginning with term: Diabetic
19-Nor-1,25$(OH)_2D_2$ (calcitriol analog), PTH secretion suppressed by, in uremia in absence of hypercalcemia, 852-860
Norepinephrine, circadian BP variations and, 718, 719
Normal body weight (BW), defined, urea kinetics and, 964-965
Normal population, *see* General population
NS, *see* Nephrotic syndrome
Number of ESRD care facilities, USRDS 1995 ADR on, S2:157
Nutrition, *see* Enteral nutrition; Malnutrition on HD and/or CAPD; Parenteral nutrition *and entries beginning with terms*: Dietary, Nutritional
Nutritional intake, low, and malnutrition on HD and/or CAPD, 230
Nutritional intervention
  in ARF, 571-573
  for malnutrition on HD and/or CAPD, 260
  see also Enteral nutrition; Parenteral nutrition; Supplementation

O_2^- (superoxide) production, effects of HCO_3- versus lactate-based PDFs on, in CAPD, 927
Obstructive nephropathy, tubulointerstitial fibrosis in, macrophage infiltration and, 133-145
  macrophage infiltration as mediator in, 133-140
  and role of angiotensin II, 141-145
Occlusive disorders, *see* Occlusive glomerulonephritis; Sneddon's syndrome, as arterio-occlusive disorder
Occlusive glomerulonephritis (GN), massive cryoglobulinemic-, heat-insoluble cryoglobulin in, 654-657

$1,25(OH)_2D_2$, *see* Calcitriol
Oligonephropathy, acquired, diabetic nephropathy and, 898-903
Oncotic pressure
  effects of, on apolipoprotein A-I metabolism in NS, 178-186
  rIL-2 and dopamine effects on, 30, 31
Optimal dosing of rHuEPO, S1:5-8
Organizational structure of USRDS, S2:20
Osmotic fragility, globular, L-carnitine and rHuEPO therapy effects on, 759, 760
Osteitis fibrosa
  and role of parathyroid glands in uremia, 808-813
  and symptomatic hypercalcemia in diabetic ESRD patient on CAPD, 831-835
Osteocalcin, serum, and bone turnover in ESRD patients on CAPD, 627
Osteodystrophy, renal, and serum PTH levels in CAPD patients, 622-631
Osteolysis, carpotarsal, with nephropathy, long-term HD for, 788-791
Outcome
  of alternate-day prednisone and fish oil supplementation in IgA nephropathy, 795
  long-term, *see* Follow-up; Long-term survival
  lupus nephritis, 300-307
  of percutaneous renal biopsy, 580-585
  see also Mortality; Patient survival; Prognosis; Recovery; Renal allograft survival *and specific conditions*
Oxalate deposition, renal function deterioration secondary to, in diabetic gastroenteropathy, 68-71
Oxidation, low-density lipoprotein, and activation of glomerular macrophages in GN, 362-367

P (phosphorus)
  in ARF patients on HCO_3-based CRRT, 913
  19-nor-$1,25(OH)_2D_2$ effects on, 855
  and rhGH therapy of malnutrition on HD and/or CAPD, 263
  serum, and bone turnover in ESRD patients on CAPD, 627
  in severe hypercalcemia with renal failure, 675
  and survival on PD and HD, 223
  see also Parathyroid hormone, Ca, P and
PAF (platelet-activating factor) in GN, 544-546
Pain, acute abdominal, hepatic infarction and, in SLE patients on HD, 785-787
Parathyroid glands
  role of, in uremia, 808-813
  see also Parathyroid glands, history of
Parathyroid glands, history of, 801-807
  Ca connection in, 804-805
  discovery of, 803-804
  and isolation of PTH, 805-806
  and origins of endocrinology, 801-803
  renal and hemostatic effects of PTH and, 806-807
Parathyroid hormone (PTH)
  isolation of, 805-806
  LCD versus traditional Ca dialysate effects on, 633
  renal and hemostatic effects of, 806-807
  in severe hypercalcemia with renal failure, 675
  see also Hyperparathyroidism; Parathyroid hormone, Ca, P and; Serum parathyroid hormone
Parathyroid hormone (PTH), Ca, P and, 818-836, 861-872
  and cAMP as mediator in Pi transport inhibition by KW-3902, 825-830
  effects of, on central nervous system, *see* Central nervous system, PTH and
  and IGF-1 effects on renal handling of P, Ca, and Na in normal population, 818-824
  introduction to, 797-800
  and pH effects on Ca transport in bladder, 866-872
  and renal afferent denervation in prevention of progression of renal disease in renal ablation model of CRF, 861-865
  and symptomatic hypercalcemia in diabetic ESRD patient on CAPD, 831-835
  see also Calcitriol; Parathyroid glands; Parathyroid hormone, Ca, P and, in dialysis patients; Target organs of PTH
Parathyroid hormone (PTH), Ca, P and, in dialysis patients, 836-851
  without aluminum toxicity, relationship between intact PTH and bone histomorphometry in, 836-844
  and dosing of IV calcitriol in dialysis patients with severe HPHT, 845-851
Parenteral nutrition
  intradialytic, *see* Intradialytic parenteral nutrition
  total, and recovery of gastric function after renal transplantation for sclerosing peritonitis secondary to CAPD, 658-661
Pathology and pathogenesis
  of antiglomerular basement membrane antibody-induced GN with multinucleated giant cells, significance of IL-6 in, 72-79
  of familial FSGS, 34-40
  of malnutrition on HD and/or CAPD, 257-259
  of renal cell carcinoma in ACKD, 6-9
  of severe hyperkalemia, 676
  see also specific conditions
Patient monitoring, of IgA nephropathy patients on alternate-day prednisone and fish oil supplementation, 794
Patient selection for rHuEPO therapy, S1:5-8
Patient survival
  with *Aspergillus* peritonitis, 80-83
  on CAPD, *see* Continuous ambulatory peritoneal dialysis, survival on
  with ESRD, *see* Patient survival, ESRD, USRDS 1995 ADR on
  on HD, *see* Hemodialysis, survival on
  with heart-lung transplants, 644
  with lupus nephritis, 300-307
Patient survival, ESRD, USRDS 1995 ADR on, S2:15-16, S2:78-83
  analytic methods to determine, S2:182-183
  comorbidity and, S2:81-82
  expected remaining years of life and, S2:82-83, S2:183
  international, S2:163-165
  long-term, S2:78-79
  pediatric, S2:123-125
  with renal transplantation, S2:96, S2:123-125, S2:180
  vascular access cost and, S2:145-146

P/C (protein to creatinine) ratio, urinary, as predictor of urinary protein excretion in IDDM, 904-909
PCO_2 in ARF patients on HCO_3-based CRRT, 913
PCR, *see* Protein catabolic rate
PD, *see* Peritoneal dialysis
PDFs (peritoneal dialysis fluids), effects of HCO_3- versus lactate-based, on peritoneal macrophage function in CAPD, 924-933
Pediatric end-stage renal disease (ESRD), USRDS 1995 ADR on, S2:16-17, S2:112-128
  causes of, S2:113-117
  causes of death in, S2:125-127
  growth and, *see* Growth and development of pediatric ESRD patients, USRDS 1995 ADR on
  incidence of, S2:112-113
  prevalence of, S2:117
  survival and, S2:123-125
  treatment modalities for, *see* Renal replacement therapy modality(ies) for pediatric ESRD, USRDS 1995 ADR on
Pediatric renal transplantation, *see* Renal transplantation, pediatric
Peptides, natriuretic, in ARF therapy, 568, 570
Percutaneous renal biopsy, outcome of, 580-585
Peritoneal dialysis (PD)
  for ESRD, *see* Peritoneal dialysis for ESRD, mortality with, USRDS 1995 ADR on
  Kt/V on, 977
  rHuEPO in, S1:4
  survival on HD and, compared, 220-228
  see also Automated peritoneal dialysis; Continuous ambulatory peritoneal dialysis
Peritoneal dialysis (PD) for ESRD, mortality with, USRDS 1995 ADR on, S2:88-93
  causes of death, S2:88-91
  mortality rate, S2:77-78
  and withdrawal from PD, S2:91-93
Peritoneal dialysis fluids (PDFs), effects of HCO_3- versus lactate-based, on peritoneal macrophage function in CAPD, 924-933
Peritoneal macrophage (PM) function, effects of HCO_3- versus lactate-based dialysate on, in CAPD, 924-933
Peritonitis
  in CAPD, *see* Peritonitis on CAPD
  S aureus and *S epidermidis*, *see*: *Staphylococcus aureus* peritonitis; *Staphylococcus epidermidis* peritonitis
Peritonitis on CAPD
  Aspergillus, therapy of, survival with, and return to CAPD, 80-83
  and CAPD effects on host defense mechanisms, 765-773
  recovery of gastrointestinal function after renal transplantation in patient with sclerosing peritonitis, 658-661
  S aureus and *S epidermidis*, 47-53, 765-773
  traditional Ca dialysate versus LCD and rate of, 632-633
  USRDS research study on, S2:171
PGs (prostaglandins), ET-1 and ET-3 interactions with NO and, 116-123
pH
  in ARF patients on HCO_3-based CRRT, 910-917
  effects of, on Ca transport in bladder, 866-872
  in severe hypercalcemia with renal failure, 675
Phagocytosis, effects of HCO_3- versus lactate-based PDFs on, in CAPD, 929-930
Pharmacodynamics (and pharmacokinetics) of DCLHb in patients on HD, 918-923
Phenotype
  apolipoprotein A, in NS, 170-177
  immuophenotyping of interstitial mononuclear cells and tubular cells in primary glomerular disease, 124-126
  thrifty phenotype hypothesis of nephron supply, 95
Phosphatase, alkaline, IV calcitriol effects on, 847
Phosphate, *see* Pi
Phosphoinositol (inositol 1,4,5-triphosphate), PTH stimulating generation of, in brain synaptosomes, 814-817
Phosphorus, *see* P
Physiology
  of RAS components, 411-416
  of skeletal muscle in CRF, 248-255
Pi (phosphate)
  L-carnitine and rHuEPO therapy effects on, 761
  KW-3902 inhibiting transport of, cAMP as mediator in, 825-830
PKD, *see* Polycystic kidney disease
Plasma albumin in CAPD patients, survival and, 356
Plasma BUN (blood urea nitrogen), effects of albuterol on, 610
Plasma cholesterol in NS, 183
Plasma glucose, fasting, in NIDDM patients, GFR and, 724
Plasma HCO_3 (bicarbonate), effects of albuterol on, 610
Plasma insulin, effects of albuterol on, 610
Plasma protein, rIL-2 and dopamine effects on, 30, 31
Plasminogen, Ancrod effects on, in SLE and DPLN, 538
Plasminogen activator, tissue, Ancrod effects on, in SLE and DPLN, 538
Platelet(s)
  Ancrod effects on, in SLE and DPLN, 538
  deposition of, on PTFE grafts and native vein fistulas, HD effects on, 614-621
  in Graves' disease, 775
  PTH effects on, 810
Platelet-activating factor (PAF) in GN, 544-546
PMØ (peritoneal macrophage) function, effects of HCO_3- versus lactate-based dialysate on, in CAPD, 924-933
Polycystic kidney disease (PKD)
  autosomal dominant, lovastatin effects in, 501-507
  epithelial-mesenchymal transformation in, 678-689
  progression of uremia and hypertension in, delayed with cilazapril, 942-946
  see also Renal cell carcinoma in ACKD
Polycythemia, enalapril for, 495-500
Polydipsia, psychogenic, due to anticholinergic drugs, CRF and, 586-589
Polymorphism
  insertion/deletion, of angiotensin I-converting enzyme gene, with IgAN, 727-731
  restriction fragment length, in analysis of metastatic renal cell carcinoma in pediatric recipient of adult cadaveric kidney, 960-962
Polyneuropathy, familial amyloid, treatment of, 279-280
Polyoma (BK) virus infection in renal allografts, renal biopsy of, 671-673
Polysulfone membranes, high-flux, for vancomycin removal in critically ill ESRD patients on HD, 469-474

Polytetrafluoroethylene (PTFE) grafts in HD
HD effects on platelet deposition on, 614-621
thrombosis of, in ESRD patients on HD, 341-346
Posttransplantation conditions and interventions, *see specific types of transplantation*
Posture, and changes in renin, aldosterone, and norepinephrine, 718
Potassium, *see* K
Prealbumin, serum levels of, and survival on HD and CAPD, 209-219
Predialysis creatinine (Cr) in uremic HD patients with sleep complaints, 752
Predialysis factors, and malnutrition on HD and/or CAPD, 257
Predialysis patients, rHuEPO in, S1:3
Predialysis urea in uremic HD patients with sleep complaints, 752
Predialysis weight of hypertensive ESRD patients, 462, 463
Prednisone
alternate-day supplementation with fish oil and, in young IgAN patients, 792-796
for monoclonal amyloidosis, 275-276
Pregnancy
effects of, on renal allograft function, 54-56
proteinuria as risk factor for renal function decline related to, in primary glomerular disease, 187-192
and rHuEPO therapy, *see* Pregnancy, and rHuEPO therapy
Pregnancy, and rHuEPO therapy, S1:14-15
in SLE, 781-784
Prescribed Kt/V, delivered versus, 977
Prescription of HD and/or CAPD for ESRD
USRDS 1995 ADR on, S2:60-63
vascular access thrombosis and, 343
Pressure, *see* Blood pressure; Oncotic pressure
Prevalence
of hypertension in ESRD patients on HD, 462-463
of microalbuminuria in hypertension, racial differences in, 577-579
see also Incidence; Prevalence of ESRD, USRDS 1995 ADR on
Prevalence of ESRD, USRDS 1995 ADR on, S2:13-14
analytical methods to determine, S2:174, S2:177-179
international, S2:161, S2:163
of treated ESRD, S2:30-38
Prevention
of GN progression, 535-540
of malnutrition on HD and/or CAPD, 259-263
of progression of renal disease in renal ablation model of CRF with renal afferent denervation, 861-865
Primary disease
in CRF, 455
and erythrocytosis in renal transplant recipients, 496
in ESRD, *see* Primary disease in ESRD
and malnutrition on CAPD and HD, 478
and survival on PD and HD, 221, 224
in TCC associated with ACKD, 9
in uremia, 24
see also Primary glomerular disease *and specific conditions*
Primary disease in ESRD
AVF thrombosis and, 348
hypertension and, 464
and rHuEPO therapy, 332
see also Primary disease in ESRD, USRDS 1995 ADR on
Primary disease in ESRD, USRDS 1995 ADR on
in Medicare and non-Medicare patients, S2:33, S2:35
in pediatric ESRD patients, S2:116
treatment incidence and, S2:43-48
vascular access type and, S2:144
Primary glomerular disease
immunophenotyping of interstitial mononuclear leukocytes and tubular cells in, 124-126
proteinuria as risk factor for decline of pregnancy-related renal function in, 187-192
see also specific conditions
Prognosis
of hypertensive diabetic nephropathy, 104
of lupus nephritis, 300-307
of renal cell carcinoma in ACKD, 7-8
with SRA, 602-606
tubulointerstitial damage in GN and, 127
see also Outcome
Progression
to calcific mitral stenosis in ESRD, 956-959
see also Progression of renal disease
Progression of renal disease, 124-140
of ADPKD, lovastatin effects on, 501-507
of GN, glomerular thrombosis and, 535-540
in hydronephrosis, macrophage infiltration and, 133-140
prevention of, in renal ablation model of CRF, renal afferent denervation in, 861-865
role of tubulointerstitial damage in GN in, 124-132
of uremia in PKD, cilazapril delaying, 942-946
Progressive renal insufficiency following cardiac transplantation, role of CsA, lipids, and hypertension in 193-201
Proliferative lupus nephritis, diffuse, glomerular thrombosis and, 535-540
Propylthiouracil for Graves' disease, 774-780
Prostacyclin, ET-1 and ET-3 interactions with, 116-123
Prostaglandins (PGs), ET-1 and ET-3 interactions with NO and, 116-123
Protein
C-reactive, in MPO-ANCA-positive crescentic GN with Graves' disease, 755
dietary, *see* Dietary protein
levels of, and survival on PD and HD, 221, 223, 224
long-lived ECM, AGE products effects on, 877-878
metabolism of skeletal muscle, in CRF, 249-250
plasma, rIL-2 and dopamine effects on, 30, 31
total, *see* Total protein
urinary excretion of, *see* Proteinuria; Urinary excretion, protein
see also entries beginning with term: Protein *and specific proteins*
Protein catabolic rate (PCR)
in CAPD patients, survival and, 355, 356
and rhGH therapy of malnutrition on HD and/or CAPD, 263
Protein catabolism
and malnutrition on HD and/or CAPD, 233-238
synthesis and, in NS, 178-186
see also Protein catabolic rate
Protein to creatinine (P/C) ratio, urinary, as predictor of urinary protein excretion in IDDM, 904-909

Proteinase-3 in RPGN, 439-445
Proteinuria
in GN, tubulointerstitial damage and, 127-128
in HIV-associated nephropathy, 286-291, 448
in hypertension, racial differences in prevalence of, 577-579
in IgAN, 728
lung transplantation and, 527-531
in NS, 172, 173, 178-186
and renal relapse in SLE, 434
as risk factor for pregnancy-related renal function decline in primary glomerular disease, 187-192
in triazolam-induced AIN with NS, eosinophilic infiltration with, 62-67
see also Albuminuria; Urinary excretion, protein
Proteolytic pathways in metabolic acidosis, 244
Proton, pH effects on secretion of, 867
Proximal tubular cells
cAMP as mediator in Pi transport inhibition by KW-3902 in, 825-830
ET-1 synthesis and secretion in, effects of albumin, IgG, and transferrin on, 934-941
Pseudohypoxia, diabetic, 202-208
Psychogenic polydipsia (compulsive water drinking) due to anticholinergic drugs, CRF and, 586-589
PTFE grafts, *see* Polytetrafluoroethylene grafts in HD
PTH, *see* Parathyroid hormone
Pyelonephritis, urinary excretion of sIgA and free secretory component in, 590-594

Race and ethnicity
of CAPD and/or HD patients, *see* Race and ethnicity of CAPD and/or HD patients
of cardiac transplant patients, 195
of ESRD patients, *see* Race and ethnicity of ESRD patients
of familial FSGS patients, 37
glomerular hyperfiltration in Koreans with NIDDM, 722-726
of NS patients, 172
of PD patients, survival and, 221, 223, 224
of peritonitis patients, 48, 49, 51
and prevalence of microalbuminuria in hypertension, 577-579
of renal transplant recipients, *see* Race and ethnicity of renal transplant patients
U.S. trends in renal disease mortality and morbidity by (1979-1990), 313-314, 316
Race and ethnicity of CAPD and/or HD patients
with ESRD, rHuEPO therapy and, 332
receiving DCLHb, 919
survival and, 214, 221, 223, 224
Race and ethnicity of ESRD patients
and circadian variations in BP, 717, 719
and hypertension, 462
on rHuEPO therapy, 332
see also Race and ethnicity of ESRD patients, USRDS 1995 ADR on
Race and ethnicity of ESRD patients, USRDS 1995 ADR on
causes of death and, S2:89, S2:90
classification of, S2:178-179
Medicare and non-Medicare patients, S2:33, S2:35
mortality rates and, S2:73-74
of pediatric patients, S2:116
remaining years of life by, S2:83
RRT modality by, S2:56, S2:57
treatment incidence and, S2:41-42
vascular access type and, S2:143-144, S2:146
Race and ethnicity of renal transplant patients
CsA withdrawal and, 489, 491
erythrocytosis and, 496
Radiolabeled serum amyloid P (SAP) scintigraphy of amyloidosis, 268-270
of β_2M amyloidosis, 279
of monoclonal amyloidosis, 276
of reactive systemic amyloidosis, 272-273
RANTES chemokines, renal disease and, 987-988
Rapidly progressive glomerulonephritis (RPGN)
ANCAS in, *see* Antineutrophil cytoplasmic antibody(ies) in RPGN
MPO in, 13-21, 439-445
RAS, *see* Renin-angiotensin system
RBCs, *see entries beginning with element*: Erythro-
RCC (Renal Community Council), S2:7
Reactive systemic amyloidosis, treatment of, 271-274
Recirculation, *see* Cardiopulmonary recirculation; Vascular access recirculation
Recombinant human erythropoietin (rHuEPO)
in diabetic macular edema and renal insufficiency, 202-208
for ESRD and/or CRF, *see* Recombinant human erythropoietin for ESRD (and/or CRF)
in pregnancy with SLE, 781-783
Recombinant human erythropoietin (rHuEPO) for ESRD (and/or CRF), S1:1-24
administration of, *see* Administration of rHuEPO
adverse effects of, S1:9-12
L-carnitine effects on anemia in patients treated with, 757-764
clinical benefits of, S1:2-5
and clinical impact of anemia, S1:2
conclusions and recommendations on, S1:15-17
dose of, *see* Dose, rHuEPO
Fe management with, S1:8-9
iron deficiency anemia diagnosis following therapy with, 292-299
patient selection, cost-effectiveness, optimal dosing and, S1:5-8
resistance to, S1:12-15
see also Recombinant human erythropoietin for ESRD, USRDS 1995 ADR on
Recombinant human erythropoietin (rHuEPO) for ESRD, USRDS 1995 ADR on, S2:63-65
analysis of, S2:184
research study on, S2:171
Recombinant human growth hormone (rhGH) for malnutrition on HD and/or CAPD, 261-263
Recombinant human insulin-like growth factor 1 (rhIGF-1), therapy of disordered skeletal muscle metabolism in CRF with, 250-253
Recombinant insulin-like growth factor 1, *see* Insulin-like growth factor 1
Recombinant interleukin-2 (rIL-2), low-dose dopamine infu-

sions reversing ARF induced by, in cancer patients, 27-33
Recovery
of gastrointestinal function after renal transplantation in patient with sclerosing peritonitis secondary to CAPD, 658-661
from renal infarction in mixed CTD, 649-653
Recurrent arteriovenous fistula (AVF) thrombosis, ACA in maintenance HD patients associated with, 347-352
Red blood cells, *see entries beginning with element*: Erythro-
Regulatory suppressor cells, DST effects and, 709
Reimbursements
for enteral and parenteral nutrition, proposed HCFA guidelines for, 995-997
see also Medicare reimbursements for vascular access in ESRD, USRDS 1995 ADR on
Rejection, renal allograft
chronic, role of eosinophils in, 634-642
CsA withdrawal and, 487-494
Relapse, *see* Recurrent arteriovenous fistula thrombosis; Renal relapse in SLE
Related donors, *see* Living related donors, evaluation and selection of
Relative body weight (BW), defined, urea kinetics and, 965
Release of USRDS data, S2:28-29
Remaining years of life of ESRD patients, expected, USRDS 1995 ADR on, S2:82-83, S2:183
Remnant renal function, *see* Residual renal function
Removal
dialytic, *see* Dialytic removal
of β_2M, 278
Renal ablation model of CRF, prevention of progression of renal disease in, with renal afferent denervation, 861-865
Renal afferent denervation in prevention of progression of renal disease in renal ablation model of CRF, 861-865
Renal allograft
BK virus infection in, renal biopsy of, 671-673
failure of, rhuEPO and, S1:14
MPGN type I in, associated with HCV infection, 662-667
pregnancy effects on function of, 54-56
see also Rejection, renal allograft; Renal allograft survival
Renal allograft survival
CsA effects on, 487-494
see also Renal allograft survival, USRDS 1995 ADR on
Renal allograft survival, USRDS 1995 ADR on, S2:96-101
analytical method to determine, S2:183-184
cadaveric, *see* Cadaveric graft survival in ESRD, USRDS 1995 ADR on
and living-related donors, S2:97, S2:183
pediatric, S2:125
Renal biopsy
of BK virus infection in renal allograft, 671-673
fine needle aspiration, of renal cell carcinoma, 4
in HIV-associated nephropathy, 288
in identification of IgA deficiency, 520-526
of minimal change NS after CsA withdrawal in bone marrow transplant recipients, 532-534
in MPO-ANCA-positive crescentic GN with Graves' disease, 774-780
percutaneous, outcome of, 580-585
of SLE, 537
see also Histology and histopathology *and specific conditions*
Renal Biopsy Study, USRDS, S2:170-171
Renal cell carcinoma
metastatic, in pediatric recipient of adult cadaveric kidney, 960-962
see also Renal cell carcinoma in ACKD
Renal cell carcinoma in ACKD, 1-12
age, race, sex and, 2, 3, 7, 9
clinical presentation and incidence of, 3-4
diagnosis of, and screening programs for, 4-5
natural history and prognosis of, 7-8
pathology and pathogenesis of, 6-9
transitional, 9-10
treatment of, 5-6
Renal Community Council (RCC), S2:7
Renal community participation in USRDS studies, S2:167
Renal disease, *see* Nephropathy
Renal effects
of AGE products, 879
of PTH, 806-807
of RAS during development, 423-424
Renal failure
hypercalcemia and, 674-677
see also Acute renal failure; Chronic renal failure
Renal function
in acquired oligonephropathy with diabetic nephropathy, 898-903
circadian variations in BP versus, 716-721
deterioration of, secondary to oxalate deposition in diabetic gastroenteropathy, 68-71
dietary cholesterol effects on, 153
in primary glomerular disease, proteinuria as risk factor for decline of, related to pregnancy, 187-192
residual, *see* Residual renal function
see also Renal insufficiency *and specific aspects of renal function*
Renal handling of P, Ca, and Na in normal population, IGF-1 effects on, 818-824
Renal infarction in mixed CTD, recovery from, 649-653
Renal insufficiency
in ADPKD, lovastatin effects on, 501-507
in HIV-associated nephropathy, 286-291
progressive, following cardiac transplantation, role of CsA, lipids, and hypertension in 193-201
and renal infarction in mixed CTD, 649-653
rHuEPO in diabetic macular edema and, 202-208
in Sneddon's syndrome, 368-372
Renal malignancy
epithelial-mesenchymal transformation in, 678-689
see also Renal cell carcinoma
Renal osteodystrophy, and serum PTH levels in CAPD patients, 622-631
Renal relapse in SLE
changes in antibodies to C1q and double-stranded DNA in, 595-601
relationship between urinary red and white blood cell casts and onset of, 432-438
Renal replacement therapy (RRT)

continuous, *see* Continuous renal replacement therapy
Lp(a) in patients on, 162-169
see also Dialysis; Renal replacement therapy for ESRD, USRDS 1995 ADR on; Renal transplantation
Renal replacement therapy (RRT) for ESRD, USRDS 1995 ADR on
on methods, S2:15; *see also* Renal replacement therapy modality(ies) for ESRD, USRDS 1995 ADR on
1992 statistics on, S2:14
on patient survival, S2:15-16
Renal replacement therapy (RRT) modality(ies) for ESRD, USRDS 1995 ADR on, S2:51-68
by age, sex, and race, S2:56-S2:57
mortality rate with, S2:85-86, S2:174, S2:180-182
options in, S2:51-52; *see also* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1995 ADR on; Hemodialysis for ESRD, USRDS 1995 ADR on; Renal transplantation for ESRD, USRDS 1995 ADR on
rHuEPO with, S2:63-65
sequential modality uses, S2:57-58
vascular access and, S2:66-67
year end modality use, S2:52-56
see also International renal replacement therapy modality (ies) for ESRD, USRDS 1995 ADR on; Renal replacement therapy modality(ies) for pediatric ESRD, USRDS 1995 ADR on; Treated end-stage renal disease, USRDS 1995 ADR on
Renal replacement therapy (RRT) modality(ies) for pediatric ESRD, USRDS 1995 ADR on, S2:117-125
patient survival and, S2:123-125
renal transplantation as, *see* Renal transplantation, pediatric, for ESRD, USRDS 1995 ADR on
Renal tissue, loss of metabolizing, and malnutrition on HD and/or CAPD, 236
Renal transplantation
A elegans infection in, 381-384
for amyloidosis, *see* Renal transplantation for amyloidosis
effects of, on Lp(a) levels, 165-166
enalapril in treatment of erythrocytosis following, 495-500
IgA deficiency and, 520-526
rHuEPO and, *see* Renal transplantation, rHuEPO and
tolerance to, *see* Donor-specific transfusion and
see also Donor(s); Immunosuppression; Renal allograft; Renal transplantation for ESRD, USRDS 1995 ADR on
Renal transplantation, pediatric
for CRF, with adult cadaveric kidney, metastatic renal cell carcinoma in, 960-962
see also Renal transplantation pediatric, for ESRD, USRDS 1995 ARD on
Renal transplantation, pediatric, for ESRD, USRDS 1995 ADR on, S2:119-125
access to, S2:119-123
allograft survival and, S2:125
patient survival and, S2:123-125
Renal transplantation, rHuEPO and, S1:5
graft failure with, S1:14
for idiopathic dialysis ascites, 668-670
lymphoproliferative disorder due to EBV of donor origin following, 84-87
recovery of gastrointestinal function after, in patient with sclerosing peritonitis secondary to CAPD, 658-661
Renal transplantation for amyloidosis, 281
for β_2M amyloidosis, 279
for monoclonal amyloidosis, 277
Renal transplantation for ESRD, USRDS 1995 ADR on, S2:16, S2:95-111
ABO blood type and, S2:102-103
access to, S2:105-110
allograft survival with, *see* Renal allograft survival, USRDS 1995 ADR on
and HLA matching, S2:101-102
international, S2:163
kidney supply and, S2:103-105
mortality with, S2:90-91, S2:182
patient survival with, S2:96, S2:123-125, S2:180, S2:183
see also Renal transplantation, pediatric, for ESRD, USRDS 1995 ADR on
Renal trihexosylceramide (CTH), accumulation of, in Fabry's disease, 952-955
Renal tubules, *see* Tubules
Renal vasculitis associated with ciprofloxacin, 516-519
Renalin, rinsing time of reused dialyzers and release of, 549-553
Renin
biochemistry and physiology of, 411-412
and circadian BP variations, 718, 719
expression of genes of, during development, 417-420
see also Renin-angiotensin system
Renin-angiotensin system (RAS)
in PKD, 942-946
see also Renin-angiotensin system during development
Renin-angiotensin system (RAS) during development, 409-431
angiotensin-generating cascades in, 409-411
biochemistry and physiology of components of, 411-416
circulating, 422-423
expression of genes of, 416-421
function of angiotensins in, *see* Angiotensin(s), development and
hemodynamic and renal actions of, 423-424
Requests
for living kidney donors, 390-391
for USRDS data, S2:24-25
Research
investigator initiated, policy on USRDS data release for, S2:28-29
see also Research studies on ESRD of USRDS, 1995 ADR on
Research studies on ESRD of USRDS, 1995 ADR on, S2:19, S2:167-173
current, S2:167-169
existing data studies as, S2:172-173
renal community participation in, S2:167
special, S2:170-172
Residual (remnant) renal function
in CAPD patients, survival and, 354, 355
and dialysis dose, 973
and uninephrectomy in adulthood, 889-897
Resistance to rHuEPO, S1:12-15
Restless legs syndrome (RLS) in uremic HD patients, 751-756
Restriction fragment length polymorphism, analysis of meta-

static renal cell carcinoma in pediatric recipient of adult cadaveric kidney with, 960-962
Reticulocyte count, enalapril effects on, 497
Retinopathy, diabetic, pseudohypoxia and, 202-208
Reused dialyzers, rinsing time and release of formaldehyde, hypochlorite, warexin, and renalin, 549-553
rhGH (recombinant human growth hormone) for malnutrition on HD and/or CAPD, 261-263
rhIGF-1 (recombinant human insulin-like growth factor 1), therapy of disordered skeletal muscle metabolism in CRF with, 252-253
Rhizotomy, and renal ablation model of CRF, prevention of progression of renal disease with renal afferent denervation in, 861-865
rHuEPO, *see* Recombinant human erythropoietin
Ribonucleic acid (RNA), messenger, different expression of, between leukocytes and fibroblasts in Alport's syndrome, 732-739
rIL-2 (recombinant interleukin-2), low-dose dopamine infusions reversing ARF induced by, in cancer patients, 27-33
Rinsing time of reused dialyzers, and release of formaldehyde, hypochlorite, warexin, and renalin, 549-553
Risk factor(s), 187-201
  Lp(a) levels as, for atherosclerosis, 166-167
  for peritonitis on APD and CAPD, 48-50
  for progressive renal insufficiency following cardiac transplantation, 193-201
  proteinuria as, for pregnancy-related renal function decline in primary glomerular disease, 187-192
  vascular access thrombosis, in ESRD patients on HD, 342
RLS (restless legs syndrome) in uremic HD patients, 751-756
RNA (ribonucleic acid), messenger, different expression of, between leukocytes and fibroblasts in Alport's syndrome, 732-739
RPGN, *see* Rapidly progressive glomerulonephritis
RRT, *see* Renal replacement therapy

S aureus peritonitis, *see*: *Staphylococcus aureus* peritonitis
S epidermidis peritonitis, *see*: *Staphylococcus epidermidis* peritonitis
Safety
  of alternate-day prednisone and fish oil supplementation in IgA nephropathy, monitoring of, 794-795
  of DCLHb in HD patients, 918-923
SAFs (Standard Analysis Files), USRDS, S2:25-28
SAP (serum amyloid P), *see* Radiolabeled serum amyloid P scintigraphy of amyloidosis
Sarcoidosis, interstitial nephritis and, multiorgan involvement in, 947-951
SC (subcutaneous) recombinant human erythropoietin (rHuEPO) for HD patients with ESRD, IV rHuEPO versus, 331-340
Scatter factor/hepatocyte growth factor (SC/HGF) in embryonic epithelial-mesenchymal transformation, 681
Scintigraphy, *see* Radiolabeled serum amyloid P scintigraphy of amyloidosis
Sclerosing peritonitis secondary to CAPD, recovery of gastrointestinal function after renal transplantation in patient with, 658-661
Screening
  of living kidney donors for familial renal disease, 393-394
  for renal cell carcinoma in ACKD, 4-5
  see also Diagnosis
Secondary glomerular disease, immunophenotyping of interstitial mononuclear leukocytes and tubular cells in primary and, 124-126
Secondary hyperparathyroidism in uremia, 19-nor-1,25$(OH)_2D_2$ for, 852-860
Secretory IgA (immunoglobulin A), urinary excretion of free secretory component and, in pyelonephritis, 590-594
Seizures, as adverse effect of rHuEPO, S1:11
Selection
  patient, for rhuEPO therapy, S1:5-8
  of unrelated living donors, 390
  see also Living related donors, evaluation and selection of
Sensitization, DST and, 705-706
Sequential renal replacement therapy (RRT) modality use, USRDS 1995 ADR on, S2:57-58
Serum albumin
  and Fe deficiency anemia following rHuEPO administration for CRF, 295
  levels of, and survival on HD and CAPD, 209-219
  in NS, 172, 173
Serum alkaline phosphatase, and bone turnover in ESRD patients on CAPD, 627
Serum amyloid P, *see* Radiolabeled serum amyloid P scintigraphy of amyloidosis
Serum Ca (calcium)
  and bone turnover in ESRD patients on CAPD, 627
  IV calcitriol effects on, 847
Serum cholesterol
  dietary cholesterol effects on, 153
  levels of, and survival on HD and CAPD, 213, 214
Serum complement (C) in HIV-associated ICGN, 448
Serum creatinine (Cr)
  in acquired oligonephropathy patients, 900
  L-carnitine and rHuEPO therapy effects on, 761
  in CRF, hepatitis B vaccination associated with tetanus immunization and, 456
  and CsA withdrawal in stable renal transplant recipients, 491
  dietary cholesterol effects on, 153
  enalapril effects on, 497
  in heart-lung transplant recipients, 644
  in HIV-associated nephropathy, 448
  in hypertension with microalbuminuria, 578
  in IgAN, 728
  in lupus nephritis, 302
  19-nor-1,25$(OH)_2D_2$ effects on, 855
  renal afferent denervation effects on, 862
  in renal allograft recipients with MPGN type I, 664
  and renal relapse in SLE, 434
  rHuEPO effects on, 203
  and uninephrectomy in adulthood, 890-892
Serum cryoglobulin in renal allograft recipients with MPGN type I, 664
Serum ferritin in Fe deficiency anemia following rHuEPO administration for CRF, 292-299
Serum glutamic oxaloacetic transaminase (SGOT), levels of, and survival on PD and HD, 221

Serum glutamic-pyruvic transaminase (SGPT), levels of, and survival in PD and HD, 221, 223, 224
Serum IgA (immunoglobulin A) in HIV-associated nephropathy, 448
Serum IgG (immunoglobulin G) in HIV-associated nephropathy, 448
Serum IgM (immunoglobulin M) in HIV-associated nephropathy, 448
Serum K (potassium)
in compulsive water drinking patients, 587
enalapril effects on, 497
hypertension and acute decrease in, in HD patients, 321-326
Serum Na (sodium) in compulsive water drinking patients, 587
Serum osteocalcin, and bone turnover in ESRD patients on CAPD, 627
Serum P (phosphorus)
and bone turnover in ESRD patients on CAPD, 627
IV calcitriol effects on, 847
Serum parathyroid hormone (PTH)
and chronic dialysis for ESRD, 627
levels of, and bone turnover in CAPD patients, 622-631
Serum prealbumin, levels of, and survival on HD and CAPD, 209-219
Serum urea nitrogen
in measurement of Kt/V in HD, 975-976
in SLE and DPLN, 539
Severe hypercalcemia, renal failure and, 674-677
Severe hyperparathyroidism (HPHT), IV calcitriol dosing in dialysis patients with, 845-851
Sex
of acquired oligonephropathy patients, 899
of CAPD and/or HD patients, *see* Sex of CAPD and/or HD patients
of cardiac transplant patients, 195
of compulsive water drinking patients, 587
of CRF patients, hepatitis B vaccination associated with tetanus immunization and, 456
of dialysis patients with aluminum intoxication, 837
of ESRD patients, *see* Sex of ESRD patients
of familial FSGS patients, 37
of heart-lung transplant recipients, 644
heterozygous females with Fabry's disease and renal CTH accumulation, 952-955
of HIV-associated nephropathy patients, 448
of hypertensive diabetic nephropathy patients, 100, 104
of IgAN patients, 728
of NIDDM patients, GFR and, 724
of NS patients, 172
of PD patients, survival, 221, 223, 224
of peritonitis patients, 48, 633
of pyelonephritis patients, 597
of renal transplant patients, *see* Sex of renal transplant patients
trends in renal disease mortality and morbidity in U.S. by (1979-1990), 313-315
of uninephrectomized patients in adulthood, 891-894
of uremic patients, *see* Sex of uremic patients
Sex of CAPD and/or HD patients
with ESRD, rHuEPO therapy and, 42, 332
of maintenance HD patients, AVF thrombosis and, 348
malnutrition and, 478
receiving DCLHb, 919
survival and, 221, 223, 224
Sex of ESRD patients
of critically ill ESRD patients on HD, vancomycin removal and, 470
and hypertension, 462
on rHuEPO therapy, 42, 332
see also Sex of ESRD patients, USRDS 1995 ADR on
Sex of ESRD patients, USRDS 1995 ADR on
causes of death and, S2:89, S2:90
expected remaining years of life by, S2:82
Medicare and non-Medicare patients, S2:33, S2:35
mortality rate and, S2:74-75
of pediatric patients, S2:116
by RRT modality, S2:56, S2:57
treatment incidence and, S2:42-43
vascular access type, S2:143-144, S2:146
Sex hormones
effects of, on mesangial cells, 147-151
see also specific sex hormones
Sex of renal transplant recipients
CsA withdrawal and, 489, 491
erythrocytosis and, 496
Sex of uremic patients, 24
with sleep complaints on HD, 752-756
SGNA (Subjective Global Nutritional Assessment) of HD and CAPD patients, 475-486
SGOT (serum glutamic oxaloacetic transaminase), levels of, and survival on PD and HD, 221
SGPT (serum glutamic-pyruvic transaminase), levels of, and survival on PD and HD, 221, 223, 224
SHR (standard hospitalization rate), S2:133-139
sIgA (secretory IgA), urinary excretion of free secretory component and, in pyelonephritis, 590-594
Skeletal muscle
altered physiology of, in CRF, 248-255
PTH effects on, 810
SLE, *see* Systemic lupus erythematosus
Sleep complaints in HD patients, 751-756
Sneddon's syndrome (idiopathic livedo reticularis), as arterio-occlusive disorder
cerebral blood vessel occlusion, livedo racemosa, and nephropathy with, 511-515
as systemic arterio-occlusive disorder, 368-372
Social cost of vascular access revision, S2:151
Sodium, *see* Na
Software needed for SAF use, S2:27
Solid-phase assays of ANCAs and anti-GBM antibodies in RPGN, 441-442
Solitary native kidney, outcome of percutaneous renal biopsy of, 580-585
Special studies, USRDS, S2:170-172
Special Studies Standard Analysis File (SAF), S2:26
Splicing mutations, COL4A5 gene, in Alport's syndrome, 732-739
SRA (superficial repositioning of artery) for chronic HD, indications for, and prognosis with, 602-606
Standard Analysis Files (SAFs), USRDS, S2:25-28
Standard hospitalization rate (SHR), S2:133-139

Standard population in USRDS 1995 ADR, S2:13, S2:174
Standardization (adjustment) of rates in USRDS 1995 ADR, S2:13, S2:179-180
Staphylococcus aureus (S aureus) peritonitis
  in APD, 47-53
  in CAPD, 47-53, 765-773
Staphylococcus epidermidis (S epidermidis) peritonitis
  in APD, 47-53
  in CAPD, 47-53, 765-773
States, *see* Networks, ESRD
Stenosis, calcific mitral, progression to, in ESRD, 956-959
Stent, infection of subclavian venous, in HD patient, 377-380
Streptokinase for acute myocardial infarction, ARF following, 508-510
Stroke, ischemic, in Sneddon's syndrome, 368-372
Subclavian venous stent, infection of, in HD patient, 377-380
Subcutaneous (SC) recombinant human erythropoietin (rHuEPO) for HD patients with ESRD, IV versus, 331-340
Subjective Global Nutritional Assessment (SGNA) of HD and CAPD patients, 475-486
Superficial repositioning of artery (SRA) for chronic HD, indications for, and prognosis with, 602-606
Superoxide (O_2^-) production, effects of HCO_3- versus lactate-based PDFs on, in CAPD, 927
Supplementation
  alternate-day prednisone and fish oil, in young IgAN patients, 792-796
  chronic intravenous Fe, rHuEPO dose with, in ESRD patients on HD, 41-46
  EAA and NEAA, in ARF therapy, 572-573
Supply, kidney, *see* Kidney supply
Supportive treatment of amyloidosis
  of β_2M amyloidosis, 278
  of monoclonal amyloidosis, 277
Surgery of amyloidosis
  of β_2M amyloidosis, 278
  of reactive amyloidosis, 274
  see also Renal transplantation
Survival
  of vascular access for ESRD, USRDS 1995 ADR on, S2:146-148
  see also Outcome; Patient survival; Prognosis; Renal allograft survival
Symptom(s), *see* Clinical features and presentation; Symptomatic hypercalcemia
Symptomatic hypercalcemia in diabetic patients on CAPD, 831-835
Synaptosomes, brain, PTH stimulating generation of inositol 1,4,5-triphosphate in, 814-817
Syndrome X, essential hypertension, nephron number and, 95-96
Systemic amyloidosis, reactive, treatment of, 271-274
Systemic arterio-occlusive disorder, Sneddon's syndrome as, 368-372
Systemic lupus erythematosus (SLE), 781-787
  glomerular thrombosis in, 536-538
  HD for, hepatic infarction in, 785-787
  IgA deficiency in, 520-526
  pregnancy with, rHuEPO therapy of, 781-784
  see also Renal relapse in SLE
Systolic blood pressure, *see* Blood pressure

T cells, DST effects on
  activation and recognition of T cells as, 702-704
  alterations of subsets of T cells as, 709
Tape drive needed for SAF use, S2:27
Target Hb (hemoglobin), rHuEPO and, S1:7-8
Target organs of PTH, 808-811
  nonclassical, 809-812
TCC (transitional cell carcinoma) in ACKD with ESRD, 9-10
Testosterone, effects of, on mesangial cells, 147-151
Tetanus immunization associated with hepatitis B vaccination in CRF, 454-460
TGF-β, *see* Transforming growth factor-β in obstructive nephropathy
Therapy
  ACE inhibitor, *see* Angiotensin-converting enzyme inhibitor(s)
  albuterol, effects of, on dialytic K removal, 607-613
  aminoguidine, advanced glycosylation inhibited by, 884
  amphotericin B liquid complex, for *A elegans* infection in renal transplant recipients, 381-384
  amyloidosis, *see* Amyloidosis, treatment of
  Ancrod, effects of, on SLE and DPLN, 538
  anticholinergic, compulsive water drinking due, CRF and, 586-589
  antihypertensive, *see* Antihypertensive therapy
  APS, in renal infarction with mixed CTD, 651-652
  of ARF, *see* Therapy of ARF
  of *Aspergillus* peritonitis, 80-83
  ciprofloxacin, renal vasculitis associated with, 516-519
  dopamine, *see* Dopamine
  interferon-α, of MPGN type I in renal allograft, 662-667
  lovastatin, *see* Lovastatin
  low-dose transdermal estrogen, effects of, on BT and bleeding in uremia, 22-26
  of lupus nephritis, 303
  of malnutrition on HD and/or CAPD, 259-263
  nephrectomy as, *see* Nephrectomy
  nutritional, *see* Nutritional intervention
  preventive, *see* Prevention
  propylthiouracil, for Graves' disease, 774-780
  of renal cell carcinoma in ACKD, 5-6
  renal replacement, *see* Renal replacement therapy
  rhIGF-1, of disordered skeletal muscle metabolism in CRF, 252-253
  rHuEPO, *see* Recombinant human erythropoietin
  of severe hyperkalemia, 676-677
  streptokinase, for acute myocardial infarction, ARF following, 508-510
  triazolam, AIN induced by, 62-67
  of tubulointerstitial damage in GN, 129-130
  vancomycin, in critically ill ESRD patients on HD, high-flux polysulfone membranes for removal of, 469-474
  see also Treated end-stage renal disease, USRDS 1995 ADR on *and specific conditions*
Therapy of ARF, 566-574

CAPD as, in ARF following streptokinase for acute myocardial infarction, 508-510
conclusion on, 573-574
with dialysis, 570-571
with diuretics, 567-569
goals of, 566-567
in ICU, HCO_3-based dialysate in CRRT of ARF, 910-917
nutritional, 571-573
with vasoactive agents, 568-570
Thrifty genotype hypothesis of nephron supply, 94-95
Thrifty phenotype hypothesis of nephron supply, 95
Thrombosis
glomerular, and progression of GN, 535-540
vascular, and hepatic infarction in HD patients with SLE, 785-787
see also Thrombotic microangiopathy; Vascular access thrombosis
Thrombotic microangiopathy, ANCA-positive crescentic GN and, 385-386
Thromboxane (Tx), ET-1 and ET-3 interactions with, 116-123
Time on dialysis, *see* Duration of CAPD and/or HD
Tissue inhibitors of metalloproteinases (TIMPs), obstructive nephropathy and, 136-139
Tissue plasminogen activator (t-PA), Ancrod effects on, in SLE and DPLN, 538
Tissue responses to AGE products, 878-879
TNF-α (tumor necrosis factor-α) in antiglomerular basement membrane antibody-induced GN with multinucleated giant cells, 74
Tolerance to renal transplantation, *see* Donor-specific transfusion
Total body water, defined, urea kinetics and, 966
Total cholesterol
L-carnitine and rHuEPO therapy effects on, 761
in NS, 172, 173
Total parenteral nutrition (TPN), and recovery of gastrointestinal function after renal transplantation in patient with sclerosing peritonitis secondary to CAPD, 658-661
Total protein
malnutrition on CAPD and HD and, 479, 480
in MPO-ANCA-positive crescentic GN with Graves' disease, 755
Touch contamination, and peritonitis on CAPD, 765-773
Toxicity, *see* Intoxication
t-PA (tissue plasminogen activator), Ancrod effects on, in SLE and DPLN, 538
Traditional Ca (calcium) dialysate, LCD versus, and rate of peritonitis, 632-633
Transdermal estrogens, effects of low-dose, on BT and bleeding in uremia, 22-26
Transferrin
effects of, on synthesis and secretion of proximal tubular cell ET-1, 934-941
in Fe deficiency anemia following rHuEPO administration for CRF, 292-299
malnutrition on CAPD and HD and, 479, 480
Transformation of epithelium to mesenchyme, 678-689
Transforming growth factor-β (TGF-β) in obstructive nephropathy
expression of, 135-136
and role of angiotensin II in tubulointerstitial fibrosis, 141-145
Transfusion, *see* Donor-specific transfusion
Transitional cell carcinoma (TCC) in ACKD with ESRD, 9-10
Transplant Standard Analysis File (SAF), S2:25-26
Transplantation, *see* Bone marrow transplantation; Heart transplantation; Lung transplantation; Renal transplantation
Treated end-stage renal disease (ESRD), USRDS 1995 ADR on, S2:30-38
incidence of, *see* Incidence of treated ESRD, USRDS 1995 ADR on
in Medicare ESRD program, S2:30-33; *see also* Medicare end-stage renal disease program
prevalence of, S2:30-38
see also Renal replacement therapy for ESRD, USRDS 1995 ADR on
Treatment, *see* Therapy
Treatment History File, S2:25
Triazolam, AIN induced by, eosinophilic infiltration in NS with, 62-67
Triglycerides
L-carnitine and rHuEPO effects on, 761
levels of, and survival on PD and HD, 221
and malnutrition on CAPD and HD, 482
in NS, 172, 173
Trihexosylceramide (CTH), accumulation of renal, in Fabry's disease, 952-955
Triphosphate, inositol 1,4,5-, PTH stimulating generation of, in brain synaptosomes, 814-817
Tubular atrophy, tubular damage and interstitial mononuclear leukocytes in GN, 129
Tubular cells
immunophenotyping of interstitial mononuclear leukocytes and, in GN, 124-126
proximal, *see* Proximal tubular cells
Tubular effects of angiotensin II receptor antagonists and acute water loading, 108-115
Tubules
epithelial nephric, metanephric mesenchyme transformation into, 680-681
see also entries beginning with term: Tubular *and element*: Tubulo-
Tubulointerstitial damage in GN, role of, in renal disease progression, 124-132
Tubulointerstitial fibrosis, *see* Obstructive nephropathy, tubulointerstitial fibrosis in, macrophage infiltration and
Tubulointerstitial nephritis, arsenic intoxication associated with, 373-376
Tumor necrosis factor-α (TNF-α) in antiglomerular basement membrane antibody-induced GN with multinucleated giant cells, 74
Tx (thromboxane), ET-1 and ET-3 interactions with, 116-123
Type I cryoglobulinemia, essential, heat-insoluble cryoglobulin in, 654-657
Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
Type I membranoproliferative glomerulonephritis (MPGN) in renal transplant, HCV infection and, 662-667

Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus

Ultrasound (US)
continuous guidance with, in percutaneous renal biopsy, outcome and, 580-585
Doppler echocardiography of calcific mitral stenosis in ESRD, 956-959
of renal cell carcinoma, 4
Unidirectional Ca^{45} (calcium^{45}) fluxes in bladder, pH effects on, 866-872
Uninephrectomy in adulthood, follow-up on, 889-897
United States Renal Data System (USRDS)
committees of, S2:6-7, S2:20-22
data of, *see* Data, USRDS
database of, S2:22-23
on Internet World Wide Web, S2:23
methodology used by, S2:24; *see also* Analytical methods used in USRDS 1995 ADR
organizational structure of, S2:20
products of, S2:23, S2:24
project goals of, S2:20
SAFs of, S2:25-28
who's who in, S2:5-8
see also United States Renal Data System, 1995 ADR of
United States Renal Data System (USRDS), 1994 ADR of
differences between 1995 ADR and, in analytical methods used, S2:174-175
errata for, S2:19
United States Renal Data System (USRDS), 1995 ADR of
introduction to, S2:1-3
list of common acronyms used in, S2:9-11
summary of, S2:12-19
see also Analytical methods used in USRDS 1995 ADR; Cost and cost-effectiveness of ESRD care, USRDS 1995 ADR on; Facilities for ESRD care, USRDS 1995 ADR on; Hospitalization for ESRD, USRDS 1995 ADR on; Incidence of treated ESRD, USRDS 1995 ADR on; International renal replacement therapy modality(ies) for ESRD, USRDS 1995 ADR on; Mortality, ESRD, USRDS 1995 ADR on; Patient survival, ESRD, USRDS 1995 ADR on; Pediatric end-stage renal disease, USRDS 1995 ADR on; Prevalence of ESRD, USRDS 1995 ADR on; Renal replacement therapy for ESRD, USRDS 1995 ADR on; Research studies on ESRD of USRDS, 1995 ADR on; Treated end-stage renal disease, USRDS 1995 ADR on; Vascular access for ESRD, USRDS 1995 ADR on
Unrelated living donors, evaluation and selection of, 390
Urea
L-carnitine and rHuEPO therapy effects on, 761
predialysis, in uremic HD patients with sleep complaints, 752
see also Urea kinetics; Urea nitrogen; Urea reduction ratio
Urea kinetics, 963-981
anthropometric parameters and, 964-967
dietary protein intake and, 967-971
and estimation of dialysis dose, 971-978; *see also* Dialysis dose
Urea nitrogen (N)
appearance of, urea kinetics and, 967-969, 978-979
in CAPD patients and/or HD patients, *see* Urea nitrogen in CAPD and/or HD patients
in critically ill ESRD patients on HD, vancomycin removal and, 470
LCD versus traditional Ca dialysate effects on, 633
serum, *see* Serum urea nitrogen
see also BUN
Urea nitrogen (N) in CAPD and/or HD patients
malnutrition and, 478
survival and, 355
Urea reduction ratio (URR), dialysis dose and, 976-977
Uremia
and cyst development, 8
effects of low-dose transdermal estrogens on BT and bleeding in, 22-26
19-nor-1,25$(OH)_2D_2$ suppressing PTH secretion in, in absence of hypercalcemia, 852-860
progression of, in PKD, delayed with cilazapril, 942-946
role of parathyroid glands in, 808-813
sleep complaints in HD patients with, 751-756
see also Chronic renal failure
Uremic anorexia, and malnutrition on HD and/or CAPD, 231-233
Ureteral obstruction, *see* Obstructive nephropathy, tubulointerstitial fibrosis in, macrophage infiltration and
Uric acid
acute water loading and angiotensin receptor antagonist effects on excretion of, 111
levels of, and survival on PD and HD, 221, 224
in severe hypercalcemia with renal failure, 675
Urinary casts, red and white blood cell, relationship between onset of renal relapse of SLE and, 432-438
Urinary excretion
of sIgA and free secretory component in pyelonephritis, 590-594
uric acid and K, acute water loading and angiotensin receptor antagonist effects on, 111
see also Urinary excretion, albumin; Urinary excretion, Na; Urinary excretion, protein *and entries ending with suffix*: -uria
Urinary excretion, albumin
dietary cholesterol effects on, 153
in NIDDM, 724
see also Albuminuria; Proteinuria
Urinary excretion, Na
acute water loading and angiotensin II receptor antagonist effects on, 108-115
rIL-2 and dopamine effects on, 30, 31
Urinary excretion, protein
Ancrod effects on, in SLE and DPLN, 538
in familial FSGS, 37
in lupus nephritis, 302
in MPO-ANCA-positive crescentic GN with Graves' disease, 755
in renal allograft recipients with MPGN type I, 664
and uninephrectomy in adulthood, 891, 892
urinary P/C ratio as predictor of, in IDDM, 904-909
see also Albuminuria; Proteinuria
URR (urea reduction ratio), dialysis dose and, 976-977
US, *see* Ultrasound
USRDS, *see* United States Renal Data System

Vaccination, tetanus, associated with hepatitis B vaccination in CRF, 454-460
Vancomycin, high-flux polysulfone membranes for removal of, in critically ill ESRD patients on HD, 469-474
Vascular access, *see* Arteriovenous fistulas; Superficial artery repositioning; Vascular access for ESRD, cost and cost-effectiveness of, USRDS 1995 ADR on; Vascular access recirculation; Vascular access thrombosis
Vascular access for ESRD, cost and cost-effectiveness of, USRDS 1995 ADR on, S2:18, S2:140-151
  of first revision, S2:148-151
  introduction to, S2:140-141
  patient survival and, S2:145-146
  study methods and materials, S2:141-143
  survival of, S2:146-148
Vascular access for ESRD, USRDS 1995 ADR on, S2:66-67
  see also Vascular access for ESRD, cost and cost-effectiveness of, USRDS 1995 ADR on
Vascular access recirculation, and dialysis dose, 973
Vascular access thrombosis
  of PTFE grafts in ESRD patients on HD, 341-346
  rHuEPO and, S1:11-12
  see also Arteriovenous fistulas, thrombosis of, on HD
Vascular disease, *see* Advanced glycosylation end products in diabetic nephropathy and diabetic vascular disease *and specific conditions*
Vascular reactivity, AGE products effects on, 879-880
Vascular rejection, chronic, of renal allograft, role of eosinophils in, 634-642
Vascular resistance, and acute serum K decreased-related hypertension, 321-326
Vascular thrombosis in SLE patients on HD, hepatic infarction and, 785-787
Vasculitis, renal, associated with ciprofloxacin, 516-519
Vasoactive agents in ARF therapy, 569-570
Vasoactive systems, effects of acute water loading on action of, 108-115
Venous stent, subclavian, infection of, on HD, 377-380
Ventricular mass, left, rHuEPO effects on, S1:8
Veto cells, DST effects and, 709
Vitamin D, *see* Calcitriol
Vitamin deficiency, as adverse effect of rHuEPO, S1:14

Warexin, rinsing time of reused dialyzers and release of, 549-553
Water drinking, compulsive, due to anticholinergic drugs, CRF and, 586-589
Water loading, acute, tubular effects of, 108-115
Weekly creatinine (Cr) clearance, dialysis dose and, 977-978
Weight
  kidney, effects of dietary cholesterol on, 153
  see also Body weight
Western blot studies of ANCAs and anti-GBM antibodies in RPGN, 442-443
White blood cells, *see* Leukocytes
Who's who in USRDS, S2:5-8
Withdrawal
  from CsA, *see* Withdrawal from CsA
  from HD of PD for ESRD, mortality and, USRDS 1995 ADR on, S2:91-93
Withdrawal from CsA
  late, in stable renal transplant recipients, 487-494
  renal biopsy of minimal change NS after, in bone marrow transplant recipients, 532-534

Xanthine, 1,3-dipropyl-8-(3-noradamantyl), cAMP as mediator in inhibition of Pi transport by, 825-830

Young patients with IgAN, alternate-day fish oil and prednisone supplementation in, 792-796

Zygomycosis in renal transplant recipients, 381-384